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Summary 
 
 
The human hepatitis B virus (HBV) is characterized by a pronounced liver tropism and a restricted 
host range. While the viral determinants essential for the host cell entry are well characterized, little 
is known about cellular factors involved in early steps of HBV infection. Proteoglycans have been 
described as primary attachment factors, but neither a receptor molecule nor the exact entry 
pathway is elucidated yet. 
Peptides comprising the first 47 amino acids (HBVpreS/2-48myr) of the preS1-domain of the HBV 
surface protein L have been shown to inhibit an infection in vitro and in vivo with high specificity. The 
full inhibitory potential of HBVpreS/2-48myr relies on the integrity of an essential region (amino acids 
9 - 15) and the presence of an acylation. This correlates with viral requirements for infectivity: 
mutations in the essential region (amino acids 11, 12 and 13) or the removal of the myristoylation 
render HBV particles non-infectious. It therefore is assumed that HBVpreS/2-48myr and the virus 
address a common factor on the hepatocyte. This work aimed to visualize and characterize the 
interaction with this factor. 
Fluorescence microscopy and flow cytometry showed that fluorescently labeled peptides 
(HBVpreS/2-48myr-K-FITC) bind to the plasma membrane of differentiated hepatocytes in a sequence- 
and myristoylation-dependent manner. The binding was not restricted to HBV-susceptible cells like 
primary hepatocytes (PH) from human or tupaia, and HepaRG cells, but was also detected on PH 
from non-permissive species (mouse, rat, dog and woodchuck). This demonstrated that a binding-
competent preS1-receptor is present also in non-susceptible species. The refractoriness of these cells 
towards HBV infection therefore must be independent from the receptor interaction. 
HBV infects only differentiated hepatocytes. Correlating to that, de-differentiation of PH was 
accompanied by a loss of the ability to bind HBVpreS/2-48myr-K-FITC. Vice versa, HepaRG cells gained 
binding competence during differentiation, demonstrating that the expression of a functional preS1-
receptor depends on the differentiation status of a cell. Sustaining this assumption, hepatoma cell 
lines like HepG2 and HuH7 did neither bind HBVpreS/2-48myr-K-FITC. Their non-permissiveness 
therefore can inter alia be explained by a lack of a functional receptor. 
To determine the affinity of the peptide-receptor interaction, binding curves for HBVpreS/2-48myr-K-
FITC-binding to the cell surface of PH were calculated with data from flow cytometry and mass 
spectrometry. This revealed a bimodal mechanism, consisting of (i) a sequence- and myristoylation-
dependent binding to a receptor with a high affinity (KD ~ 60 nM), and (ii) a non-specific, low-affinity-
interaction (KD > 2000 nM), that depended only on the myristoylation. Analysis of the binding kinetics 
on PH showed that equilibrium of the high-affinity interaction was established after 10 minutes. 
Thereby, the peptide-receptor complexes exhibited an extraordinary high stability over time (t1/2 ~ 11 
hours), which indicated a low metabolic turn-over rate. These complexes were tightly associated with 
the actin cytoskeleton, as they did not show lateral movement within the membrane after 
photobleaching and co-localized with actin. 
In order to extend these findings and to investigate the interaction of HBV particles with cells, 
fluorescently labeled HBV-Alexa488 was produced and characterized on a single-particle level. 
Chemical labeling of cell-culture derived virus yielded infectious particles of a high purity and bright 
fluorescence. Detection of HBV-Alexa488 on HepaRG cells showed a binding behavior similar to that 
of unlabeled HBV. Binding could be enhanced with PEG and inhibited by heparin. The labeled virus 
produced here can be applied for future single-virus tracing experiments. 
 
 
 
 
Zusammenfassung 
 
 
Das humane Hepatitis B Virus (HBV) zeichnet sich durch einen ausgeprägten Leber- und 
Wirtstropismus aus. Während die Bedingungen für die Infektiosität eines HBV Partikels gut 
untersucht sind, ist aufseiten der Wirtszelle nur wenig über die frühen Schritte der Infektion bekannt. 
Außer Proteoglykanen, die als primäre Bindungsfaktoren dienen, sind bisher keine zellulären 
Rezeptormoleküle identifiziert worden. 
Peptide, die  aus den N-terminalen 47 Aminosäuren (AS) der präS1-Region des HBV-
Oberflächenproteins L bestehen (HBVpräS/2-48myr), können eine Infektion in vitro und in vivo 
spezifisch inhibieren. Dabei sind eine Sequenz in der sog. essentiellen Region (AS 9 - 15), sowie eine 
Acylierung am N-Terminus Voraussetzung für die inhibitorische Aktivität dieses Peptids. Parallel 
hängt auch die Infektiosität eines HBV Partikels von diesen Faktoren ab: Rekombinante Viren, die 
Mutationen in der essentiellen Region tragen oder denen die Myristoylierung des L-Proteins fehlt, 
sind nicht infektiös. Aufgrund dieser Korrelation wird angenommen, dass HBVpräS/2-48myr und das 
Virus einen gemeinsamen Faktor auf der Hepatozyte adressieren. Ziel dieser Arbeit war es, diesen 
Faktor zu visualisieren und dessen Bindung zu charakterisieren. 
Mittels Fluoreszenzmikroskopie und Durchflusszytometrie (FACS) konnte gezeigt werden, dass 
fluoreszenz-markierte Peptide (HBVpräS/2-48myr-K-FITC) an die Plasmamembran von differenzierten 
Hepatozyten binden. Diese Bindung war von der Peptidsequenz und der Myristoylierung abhängig, 
aber nicht von der Suszeptibilität der Zielzelle. So wurde neben HBV-infizierbaren primären 
Hepatozyten von Mensch/ Tupaia und HepaRG Zellen auch eine Bindung an Hepatozyten von nicht-
infizierbaren Spezies (Maus, Ratte, Hund und Waldmurmeltier) gezeigt. Die Beständigkeit dieser 
Zellen gegenüber einer HBV Infektion kann also nicht durch das Fehlen eines präS1-Rezeptors erklärt 
werden. 
Da HBV ausschließlich differenzierte Hepatozyten infizieren kann wurde untersucht, ob es einen 
Zusammenhang zwischen dem Differenzierungsgrad und der präS1-Rezeptor Expression einer Zelle 
gibt. Es wurde gezeigt, dass Hepatozyten im Laufe der Dedifferenzierung ihre Bindefähigkeit für 
HBVpräS/2-48myr-K-FITC verlieren. Im umgekehrten Fall erlangen HepaRG Zellen diese Fähigkeit erst 
mit Erreichen eines differenzierten Zustandes. Auch Hepatoma Zelllinien, wie z.B. HepG2 oder HuH7 
Zellen, zeigten keine Bindung von HBVpräS/2-48myr-K-FITC. Die Expression eines funktionalen 
Rezeptors hängt also vom Differenzierungszustand einer Zelle ab. 
Um die Affinität der Rezeptorbindung zu bestimmen, wurden mittels FACS und Massenspektrometrie 
Bindungskurven für die Interaktion von HBVpräS/2-48myr-K-FITC mit der Plasmamembran von PH 
erstellt. Diese zeigten einen bimodalen Bindemechanismus, bestehend aus (i) einer Sequenz- und 
Myristoylierungs-abhängigen Interaktion mit einem hoch-affinen Rezeptor (KD ~ 60 nM), und (ii) einer 
unspezifischen, nur Myristoylierungs-abhängigen Bindung von geringerer Affinität (KD > 2000 nM). 
Untersuchungen zur Bindungskinetik zeigten, dass ein Reaktionsgleichgewicht bereits nach 10 
Minuten erreicht ist, und dass die Peptid-Rezeptor Komplexe mit einer langen Halbwertszeit von t1/2 
~ 11 Stunden relativ lange auf der Zelloberfläche verbleiben. Dies spricht für eine langsame 
Metabolisierung. Wie Analysen zur lateralen Mobilität und Co-Lokalisations-Experimente ergaben, 
zeigten die Peptid-Rezeptor-Komplexe dabei eine Interaktion mit dem Aktin- Zytoskelett. 
Um auch das Bindeverhalten von HBV-Partikeln untersuchen zu können, wurden durch chemische 
Kopplung von Alexa-Fluor488 Fluoreszenz-markierte, infektiöse HBV-Partikel hergestellt (HBV-
Alexa488). Diese zeigten ein Bindeverhalten auf HepaRG Zellen, ähnlich dem von nicht-markiertem 
HBV, und eignen sich für eine zukünftige Verwendung zur Untersuchung der Virusbindung und 
Virusaufnahme in Echtzeit. 
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1. Introduction 
1.1 Hepatitis B 
The term hepatitis describes an inflammation of the liver. The most common cause of hepatitis is a 
viral infection. There are five main hepatitis viruses, referred to as types A, B, C, D and E. 
A disease widely witnessed in young people accompanied by jaundice has already been mentioned 
by Hippocrates as early as 400 BC, and in 752 AD, Pope Zacharias wrote in a letter about the 
“jaundice of a contagious nature” (Hepatology - Principles and Practice, Kuntz and Kuntz, Springer 
Verlag 2002). First reports about a parenteral transmissibility of infectious jaundice were drawn up 
after an epidemic in Bremen (Lürman, 1885) and Merzig (Jehn, 1885). These epidemics developed 
after the use of a smallpox vaccine that contained a human lymph preparation. Several cases of 
epidemiological unexplained jaundice occurred within the next decades. All were preceded by a 
vaccination campaign with a measle convalescent serum, or the infusion of insulin and dextrose with 
re-used needles.  
In 1947, MacCallum discriminated the icterus epidemica as type A and the hepatitis developed onto 
inoculation as type B (MacCallum, 1947). These, at a later date, were to correspond to the hepatitis A 
virus and the hepatitis B virus. The first step towards the identification of the pathogen of hepatitis B 
came from studies of genetic polymorphisms of serum proteins by Blumberg, Alter and Bisnich 
(Blumberg et al. 1965). They detected a novel antigen in the plasma of an Aboriginal patient that 
reacted with antibodies from a hemophilia patient. This antigen, referred to as Australia antigen, was 
later brought into context with the development of hepatitis. In parallel, Prince et al. were using a 
direct approach to search for the viral cause of serum hepatitis. By immunofluorescence microscopy 
of liver tissue sections they identified a cytoplasmic staining that probably reflected an antibody 
reaction with the Australia antigen (Prince et al. 1964). They also identified a serum protein in 
patients with post-transfusion hepatitis, that later was shown to be identical to the Australia antigen 
(Prince 1968). 
In 1970, Dane et al. discovered by electron microscopy small, spherical 42 nm particles in the serum 
of patients with antigen-associated hepatitis (Dane et al. 1970). These particles turned out to 
represent infectious hepatitis B virus particles that nowadays still are described as Dane-particles. 
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1.2 Molecular Virology of the Hepatitis B Virus 
1.2.1. Classification of the Hepadnaviridae and their host range 
All members of the family of Hepadnaviridae (hepatitis DNA viruses) share remarkable similarities in 
the genome organization and the replication strategies. Along with the Spumaviridae (foamy viruses), 
they are the only known animal DNA viruses that replicate their DNA by reverse transcription of a 
viral RNA intermediate. Such viruses have otherwise been found only in plants (e.g. cauliflower 
mosaic virus). Since hepadnaviruses, like the members of the family of Retroviridae, encode a reverse 
transcriptase, both families are assigned to the group of retroid viruses. 
Hepadnaviruses are characterized by an extremely small genome (approximately 3.2 kb), a unique 
replication strategy, and a very narrow host range and tissue tropism. The family contains two 
genera, the orthohepadnaviruses, infecting mammals, and the avihepadnaviruses, infecting birds. In 
addition to host range differences, the division into two genera is based on strong DNA sequence 
similarities among all orthohepadnaviruses and all avihepadnaviruses, but an almost complete lack of 
homology between these two groups. Members of the Avihepadnaviridae include the duck hepatitis 
B virus (DHBV) and the heron hepatitis B virus (HHBV). Based on perceived differences in the host 
range, the Orthohepadnaviridae have been divided into five distinct species, the human type B 
(HBV), the woodchuck (WHV), the ground squirrel (GSHV), the arctic ground squirrel (AGSHV) and the 
woolly monkey (WMHV) hepatitis virus (see Figure 1). Human HBV exists in several genotypes that 
tend to have distinct geographic distributions. Eight genotypes have been identified, A to H, that 
show sequence diversities of up to 17 %.  
HBV isolates that are closely related in sequence to human HBV have been found also in chronically 
infected chimpanzees, gorillas, orangutans and gibbon apes (Zuckerman et al. 1978; Verschoor et al. 
2001; Thornton et al. 2001), but these primate isolates are rather considered as HBV subtypes than 
as new species. Interestingly, several studies in wild-born or captive Cercopithecidea monkeys did 
not show reactivity against serological markers of HBV (Makuwa et al. 2006; C. Huang et al. 2009), 
indicating that, if an HBV species exists in these animals, it must be highly divergent. Human isolates 
have been shown to infect gibbon apes and chimpanzees, but no convincing evidence of an infection 
of macaques or other members of the Cercopithecidea family has been described yet. Macaca 
sylvanus is able to replicate HBV in vivo post experimental transfection (Gheit et al. 2002) and a 
recent study demonstrated an HBV replication in primary macaque hepatocytes (Lucifora et al. 
2010). However, susceptibility of these animals has not been shown. 
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Figure 1: Phylogenetic tree of the Hepadnaviridae family. Depicted are the avihepadnaviridae (top) and the 
orthohepadnaviridae (bottom). The latter encompass the human hepatitis B viruses (HBV) genotypes  (A - H), 
HBV subtypes that naturally occur in apes, and the hepatitis B virus found in woolly monkeys (WMHBV), 
woodchucks (WHV), ground squirrels (GSHV) and arctic ground squirrels (AGSHV). The dendogram was 
constructed using ClustaIX. (From: Fields, Virology, 5th edition.) 
WHV, the woodchuck hepatitis B virus, is another well-studied orthohepadnavirus occurring naturally 
in marmots. Interestingly, WHV infects woodchucks, but not other rodents like ground squirrels, 
while the GSHV infects both, woodchucks and ground squirrels (Seeger et al. 1987; Seeger et al. 
1991). Although this implies an extremely restricted host range for WHV, HDV with a WHV envelope 
(wHDV) has been shown to infect chimpanzees (Gerin 2001) and primary human hepatocytes 
(Gudima et al. 2008). Vice versa, a human enveloped hHDV could enter and (transiently) infect 
woodchuck hepatocytes in vivo without the need for a helper virus (Netter et al. 1994). An infection 
of woodchucks or primary woodchuck hepatocytes with HBV has not been described. 
1.2.2. Animal models for HBV 
Chimpanzees are the only animals fully permissive for an HBV infection. Their susceptibility has been 
described firstly after induction of an acute infection by injection of serum from human HBV carriers 
(Barker et al. 1975). Although chimpanzees do not develop a chronic disease, they have seen use in 
studying the pathogenesis of an acute infection (Will et al. 1982) and played an important role in the 
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development of safe vaccines (e.g. (Berthelot et al. 1984). However, due to the strong ethical 
constraints and the high costs, the experimental use of chimpanzees has been limited. 
In 1996, tree shrews (Tupaia belangeri) have been described as the first non-primate species to be 
susceptible to human HBV infection (Yan et al. 1996; Walter et al. 1996). Although Tupaias are 
phylogenetically relative closely related to humans, they form their own order (Scandentia) within 
the mammals. Because of the accentuated host restriction of hepadnaviruses, it was surprising to 
find that Tupaias are susceptible to the human HBV. However, experimental infection of tree shrews 
is not highly efficient and causes only a mild, transient infection with low viral titers. Primary 
hepatocytes isolated from the liver of Tupaias are well susceptible to HBV infection and therefore 
provide a valuable source of HBV-permissive cells for in vitro experiments. Moreover, primary Tupaia 
hepatocytes were also used for the construction of chimeric mouse livers that could be infected with 
HBV (Dandri et al. 2005). 
Even though HBV does not infect mice, several transgenic mouse models have been developed to 
study the mechanisms of HBV replication (Araki et al. 1991) and oncogenicity of viral genes in vivo 
(Kim et al. 1991). The first transgenic mouse system that produced high levels of complete viral 
particles without any evidence of cytopathology was developed by (Guidotti et al. 1995)). Nowadays, 
several mouse models are available that are based on transduction (adenoviral gene transfer), 
transfection (hydrodynamic injection) or transplantation of HBV-susceptible cells into mice (Trimera-
mouse, implantation of permissive hepatocytes in SCID mice or uPa-transgenic mice). For an 
overview see (Dandri et al. 2006). 
1.2.3. The Structure of HBV particles 
One characteristic trait of hepadnaviruses is the presence of three different particle forms in the 
plasma of infected patients (Figure 2). Besides genome-containing, infectious Dane particles, there 
exist subviral spheres and filaments with a diameter of approximately 20 nm and different lengths. 
These non-infectious, subviral particles are released constitutively from infected cells and can reach 
titers 103 to 105 times higher than that of infectious virions (up to 1010 GE/ ml blood). Their exact role 
in the HBV life cycle is unknown, but it is assumed that they facilitate virus spread and maintenance 
in the host by adsorbing virus-neutralizing antibodies. 
The infectious Dane particle has a size of 42 - 47 nm and consists of an enveloped icosahedral 
nucleocapsid containing the viral genome. The nucleocapsid has a diameter of approximately 28 nm. 
Two types of capsids can be found after expression in E. coli (Crowther et al. 1994). The major part of 
capsids corresponds to shells of 120 core protein dimers, with a triangulation number of T = 4. A 
smaller population of capsids consists of 90 copies and corresponds to a T = 3 shell. Both particle 
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forms can be found also in patients, but infectious particles possess a T = 4 shell only (Roseman et al. 
2005; Dryden et al. 2006). 
The nucleocapsids contain a single copy of a partially double-stranded DNA genome. The viral 
polymerase is covalently coupled to its 5’-end via the terminal protein (TP). The polymerase provides 
an endogenous DNA polymerase activity with two functional domains, the reverse transcriptase (RT) 
and the RNAse H. 
 
 
Figure 2: Structure of the HBV particle forms and the envelope proteins. (A) The serum of infected patients 
contains infectious Dane particles and empty subviral spheres and filaments. Dane particles enclose the viral 
capsid, consisting of core protein (black) and protecting the partially double-stranded DNA genome (purple and 
blue). Covalently bound to the genome is the viral polymerase (green), with a reverse transcriptase domain 
(RT), an RNAse H activity and the terminal protein (TP). The capsid is enveloped by a lipid bilayer (red) that 
incorporates the envelope proteins L, M and S. Subviral particles do not contain capsids. (B) The HBV envelope 
proteins share the C-terminal S domain (red) with the transmembrane domains I - IV (yellow). The M protein 
posesses an additional preS2 sequence (orange), and the L protein is further elongated with the preS1 domain 
(pink). The L protein is modified by an N-terminal myristoylation. (Potential) glycosylation sites are indicated 
with (Y). Schematics from: Stefan Seitz. 
 
1.2.3.1. HBV envelope proteins and preS1-derived lipopeptides 
The viral envelope includes three forms of transmembrane proteins, the large (L), middle (M) and 
small (S) protein, which are incorporated together with host lipids during virus budding into the 
endoplasmic reticulum (ER). The L, M and S proteins are present on Dane particles in a ratio of about 
1:1:4 (Heermann et al. 1984). Spheres contain M and S proteins at a ratio of about 1:2 and only trace 
amounts of L, whereas filaments contain approximately equal amounts of M and L. All three 
envelope proteins are derived from one single open reading frame (ORF) and therefore share their C-
terminal S-domain (see Figure 2). 
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The M protein comprises an N-terminal extension (preS2) of 55 amino acids, and the L protein is 
further elongated by additional 108 to 119 amino acids, depending on the genotype. The latter 
domain is referred to as preS1 region. 
The S domain bears a potential N-glycosylation site at position N-146 which is used only partially. A 
second potential N-glycosylation site is located at position N-4 in the preS2 domain. Because of the 
cytosolic orientation of the preS2 domain during protein synthesis, this site is modified only in the M 
protein but not in the L protein. Threonine located at position 37 in the preS2 domain is O-
glycosylated in both, the L and M protein. 
Another important modification that is common for probably all hepadnaviral L proteins is the N-
terminal myristoylation (Persing et al. 1987). Cytoplasmic N-myristoyl transferases recognize a 
sequence within the 9 N-terminal amino acids and co-translationally attach myristate, a 14-carbon 
saturated fatty acid, to glycine at position 2. 
The role of the S protein in HBV entry is only partially understood. It is known that antibodies 
directed against the antigenic loop of the S protein can block an infection in vivo and in vitro, 
indicating that this part is involved in viral entry (Iwarson et al. 1985; Shearer et al. 1998). However, 
proteolytic removal of the preS1 regions from HBV particles results in a loss of infectivity. The S 
protein therefore is needed, but not sufficient for HBV entry.  
In contrast to the M protein, the L protein is absolutely essential for the viral infectivity. Particularly 
important are the first 77 amino acids (Le Seyec et al. 1999) and the N-terminal myristoylation  
(Gripon et al. 1995). The L-protein can exist in a dual topology that either exposes its preS1-part to 
the inner or the outer phase of an HBV particle. 
Interestingly, it has been shown that synthetic peptides comprising an N-terminal part of the preS1 
region can specifically inhibit HBV infection in vitro and in vivo (Gripon et al. 2002; Joerg Petersen et 
al. 2008). Comprehensive studies using recombinantly or synthetically produced peptides showed 
that the first 8 amino acids (19 amino acids in genotype A) and the residues 19 to 28 are dispensable 
for infection inhibition. Residues 29 to 48 enhance the inhibitory activity, and the sequence between 
amino acids 9 and 15 is absolutely essential (Gripon et al. 2005; Schulze et al. 2010). Even minor 
changes, like the substitution of L- amino acids with their respective enantiomeric D- forms, lead to a 
complete loss of activity. Correlating to that, recombinant HBV particles carrying mutations in the 
positions 11 to 13 are noninfectious (Engelke et al. 2006). This and its high conservation among all 
HBV genotypes indicate an important role of the essential region 9-NPLGFFP-15 in receptor binding. 
Also the N-terminal myristoylation is required for both, inhibitory activity of the peptide and 
infectivity of the virion. While removal of the acylation enhances the IC50 of synthetic peptides by a 
factor of ~ 1000, elongation of the fatty acid chains led to a reduction of the IC50. A detailed 
Introduction  7 
mutational analysis of the sequence requirements of preS1-mediated receptor binding has recently 
published by (Schulze et al. 2010). 
1.2.3.2. The livertropism of HBVpreS/2-48myr 
Pharmakokinetic studies of uPA/RAG-2 mice that were transplanted with susceptible primary 
hepatocytes from Tupaia belangeri showed that HBVpreS-derived lipopeptides (HBVpreS/2-48myr and 
HBVpreS/2-48stea) accumulate in the liver of those animals. Surprisingly, no preferential accumulation 
of HBVpreS/2-48myr in regions enriched in susceptible hepatocytes was detected (Petersen et al. 
2008). 
A comprehensive pharmacokinetic study of a set of mutant preS1 peptides revealed a tropism for the 
liver of normal mice and rats that completely correlated with the inhibitory activity on HBV infection 
(Alexa Schieck, diploma thesis) (see Figure 3). While the wild type peptide accumulated in the liver 
with a high efficacy, the same mutations that resulted in a loss of activity also led to a loss of liver 
specificity. Biodistribution experiments revealed that a peptide in which an amino acid in the 
essential region was mutated (G12E) was distributed over all organs. A non-myristoylated peptide 
(HBVpreS/1-48) was excreted from the body within 4 hours. 
 
 
Figure 3: The biodistribution of HBVpreS/2-48myr and inhibitory inactive mutants in mice. (A) NMRI mice were 
injected i.v. with a radioactively labeled (-YI131) HBV-inhibitory peptide HBVpreS/2-48myr (left), an inactive 
mutant HBVpreS/2-48(G12E)stea (middle) and a non-myristoylated peptide HBVpreS/1-48 with a 1000-fold 
higher IC50 (right). Organs were harvested from 3 animals per time point and radioactivity was measured in a γ-
counter. (B) Autoradiography of liver sections was performed 24 h p.i of iodinated HBVpreS/2-48myr (left) or the 
inactive derivate HBVpreS/2-48myr(D11,13) (right). Data: Alexa Schieck. 
These findings showed that HBVpreS/2-48myr is specifically retained in the liver of even non-
susceptible animals. The complete correlation of the requirements for an inhibitory activity on HBV 
infection with that for a liver tropism of the peptide indicated that HBVpreS/2-48myr binds to a 
specific factor that is expressed in the liver and plays an essential role in HBV entry. It is clear that 
primary human and Tupaia hepatocytes, as well as HepaRG cells express such a factor, since infection 
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of these cells can be inhibited with HBVpreS/2-48myr. However, these data do not allow us to exclude 
the presence of this factor also on non-parenchymal cells. 
These findings furthermore suggested a role of the preS1 part for the liver tropism of HBV virions. 
The impact of respective mutations on the liver tropism of virus particles remains to be tested. 
1.2.4. The HBV replication cycle 
1.2.4.1. HBV entry and cell culture systems 
The early steps of HBV infection are not well understood. Investigations towards HBV entry have 
been hampered by the lack of suitable cell culture systems. Studies were limited to the use of 
primary hepatocyte cultures from human or Tupaia belangeri.  
In 2002, Gripon et al. described the first human hepatoma cell line HepaRG susceptible to HBV 
infection as a result of an in vitro differentiation process. The HepaRG cell culture system is based on 
a differentiation process that is induced by DMSO and, additionally, hormones. This cell line is 
derived from a liver tumor of a chronically infected HCV patient. In contrast to other hepatoma cell 
lines (e.g. HepG2, Huh7), HepaRG cells exhibit only a few major chromosomal rearrangements, are 
pseudodiploid and therefore much less likely altered (Gripon et al. 2002b). 
HepG2 cells have been described as permissive after treatment with DMSO (Bchini et al. 1990; Paran 
et al. 2001), but these data could not be affirmed by others. However, transfection of different 
HepG2- or HuH7-derived hepatoma cell lines with an overlength HBV genome led to the production 
of infectious virions (Sells et al. 1987; Sureau et al. 1986; Tsurimoto et al. 1987; Shih et al. 1989), 
indicating that the refractoriness of these cells has to be attributed to an earlier step of infection. In 
HepG2 cells for example, a restricted nuclear import of HBV capsids has been supposed (Qiao et al. 
1994), or an overexpression of serine protease inhibitor Kazal (SPIK) (Lu & Block 2004). 
A major drawback of the use of primary hepatocyte cultures is that they lose their susceptibility 
within the first days after isolation (Gripon et al. 1988). This probably is due to a process referred to 
as dedifferentiation. It has been observed that a number of liver-specific functions are progressively 
lost with time when hepatocytes are isolated and cultivated (review Elaut et al. 2006). These 
phenotypic changes are primarily the result of fundamental changes in gene expression concomitant 
with a diminished transcription. Discussed inducers for a dedifferentiation are e.g. the stress during 
perfusion and isolation, the disruption of the normal tissue architecture and the adaptation to the 
conditions in vitro. This process can be slowed down by the presence of DMSO, a widely used 
differentiating agent that has been shown to induce a hepatocyte arrest in the cell cycle phase G1 
(Cable & Isom 1997).  
HBV binding components have been isolated from plasma membranes of primary hepatocytes or 
hepatic cell lines (e.g. HepG2), but none of these potential binding factors has convincingly been 
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shown to be essential for HBV infection. An overview about molecules discussed as potential HBV 
receptors is given in a review by (Glebe & Urban 2007). Until now, the only reliable study towards 
HBV binding factors has been described by (Schulze et al. 2007), demonstrating that 
glycosaminoglycans serve as primary attachment factors for HBV.  
Also the entry pathway of HBV is poorly understood. A recent study suggested a caveolae-dependent 
entry of HBV in HepaRG cells stably expressing dominant-negative forms of caveolin-1 and dynamin-2 
(Macovei et al. 2010). However, direct evidence for a role of these molecules for virus uptake was 
not presented. The use of chemical compounds to inhibit cellular functions such as functional 
endocytosis, acidification of endosomes or integrity of the cytoskeleton has been described widely to 
investigate viral entry mechanisms. These experiments, however, strongly manipulate natural 
cellular processes, so that secondary effects cannot be excluded and results have to be interpreted 
with caution. 
1.2.4.2. Post-entry steps of an HBV infection 
After fusion of the viral and a cellular membrane, the nucleocapsid is released into the cytoplasm. It 
then is transported to the nucleus, where a nuclear localization signal in the N-terminal region of the 
core protein facilitates nuclear import (Kann et al. 1999). Within the nuclear pore capsids dissociate 
and the viral genome (rcDNA) is released into the nucleoplasm (Rabe et al. 2003). After repair of the 
partially double stranded rcDNA genome, covalenty closed circular DNA (cccDNA) is formed and 
transcribed by the cellular RNA polymerase II. Posttranscriptional regulation does not involve 
splicing, but regulation of the transport of viral transcripts from the nucleus into the cytoplasm by a 
posttranscriptional regulatory element (PRE), where translation of the viral mRNAs takes place. 
Packaging of the pre-genomic RNA (pgRNA) is induced by binding of the viral polymerase to the 
packaging signal ε located at the 5’-end of the pgRNA. This interaction leads to the recruitment of 
core proteins and assembly of the nucleocapsid. Within the nucleocapsid, maturation of the pgRNA is 
achieved by reverse transcription to obtain rcDNA. Mature nucleocapsids can either be re-imported 
to the nucleus, enhancing the cccDNA pool, or bud to a post-ER/ pre-Golgi compartment to be 
secreted.  
In contrast to HDV budding, that involves an association of a C-terminal proline/ glycine-rich domain 
of the large delta antigen with a tryptophan-rich region in the cytosolic loop of HBV S-protein (Komla-
Soukha & Camille Sureau 2006), the budding of HBV is poorly understood. It is assumed that the HBV 
nucleocapsid interacts with an L-protein isoform that exposes the N-terminal part at the cytosolic 
side of the membrane (Bruss 2004). 
In the ER membrane, HBV surface proteins tend to accumulate posttranslationally in microdomains. 
If a critical density is reached, budding of particles can take place even in absence of nucleocapsids. 
This results in the constitutive secretion of subviral spheres and filaments. 
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1.3 Epidemiology and pathogenesis 
HBV is transmitted by a parenteral infection. The main routes of infection are perinatal transmission, 
blood and percutaneous transmission, and sexual transmission. 
Although safe vaccines are available, more than 1/3 of the current world population shows 
serological markers of an HBV infection and about 350 million people live with a chronic infection 
(WHO, revised August 2008). Hepatitis B is endemic in China, other parts of Asia and in Africa. In 
these regions, most infections occur perinatally or during the early childhood. The prevalence of HBV 
infection is shown in Figure 4. 
 
 
Figure 4: Geographic distribution of HBsAg prevalence. (From: CDC Traveler’s Health, Yellow Book 2007). 
Each year over 1 million people die from HBV-related chronic liver disease, including cirrhosis and 
hepatocellular carcinoma (HCC). HCC is one of the most common types of cancers worldwide, and 
HBV is responsible for at least 75 % of all cases.  
The severity of an HBV infection depends on different factors like e.g., the age at the time point of 
infection, the presence of co-infections with HCV, HIV or HDV, and alcohol consumption. 65 % of 
infected healthy middle-aged people do not show symptoms after HBV infection, whereas about 35 
% develop and acute hepatitis that in most cases (90 - 95 %) cures. The most typical symptom of an 
acute hepatitis is jaundice. However, 5 - 10 % of hepatitis B patients develop a chronic infection that 
in up to 1/3 of all cases can lead to a chronic liver inflammation. Chronic hepatitis B often results in 
HCC. 
The likelihood that an HBV infection will become chronic rises with younger ages. About 90 % of 
infants infected during the first year of life develop a chronic infection. 
HBV replicates almost exclusively in hepatocytes and is noncytopathic. The pathogenesis of a chronic 
infection is credit to a reaction of the immune system that is based on the recruitment of cytotoxic T-
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cells due to antigen presentation. T-cells in turn can recruit macrophages and neutrophils that induce 
an inflammation in the liver. 
1.4 Therapy 
For an acute hepatitis B there is no specific treatment. Symptoms can be relieved but a curative 
antiviral therapy generally is not applied. Chronic hepatitis B, in contrast, needs treatment aiming to 
stop progression of the disease and to improve the functions of a potentially damaged liver. Several 
effective drugs are available, but a complete clearance of an HBV infection is rare. 
1.4.1. Immune system modulators 
A widely known modulator of the immune system is interferon-α (IFN-α). Treatment for several 
months can achieve an HBeAg seroconversion in 30 - 40 % of the patients. Response to IFN-α differs 
between HBV genotypes (Erhardt et al. 2005). Whereas genotypes A and B show good response (in 
40 - 45 % of the cases) genotypes C and D show a seroconversion rate of only 15 - 25 %. In 
immuntolerant hepatitis B patients, the response is very poor (9 %). 
The use of IFN-α, that in some cases requires daily injections, has lately been supplanted by a new 
derivate. By covalent attachment of polyethylenglycol (PEG), the serum half life time of IFN-α could 
be enhanced up to 10-fold. PEGylated IFN-α (PEG-IFN-α) therefore needs only one administration a 
week. Both drugs have been shown to achieve comparable results, but due to the more comfortable 
application the use of PEG-IFN-α is preferred. 
A major drawback of the treatment with interferon is the severity of side effects. Besides a dosis-
dependent incidence of flu-like symptoms, adverse effects include e.g. bone marrow suppression and 
psychiatric complications. 
1.4.2. Antiviral drugs 
Nucleoside or nucleotide analogues compete with naturally occurring purines and pyrimidines for 
binding to the HBV DNA polymerase. Nucleotide analogues consist of a base, a sugar moiety and a 
phosphate residue, whereas nucleoside analogues lack the phosphate residue. These drugs block 
replication by terminating the polymerase reaction. 
Unlike interferon, nucleos(t)ide analogues are well tolerated by patients with hepatitis B and 
significant improvement of hepatic synthetic function has been documented. The most frequently 
used drugs are lamivudine, adefovir, entecavir, telbivudine and tenofovir. Among those the three 
latter are most potent in HBV DNA suppression. 
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Nucleos(t)ide analogues can be applied also in long-term therapy. Unfortunately, the effectiveness 
and durability of response is compromised by the emergence of mutations in the HBV DNA 
polymerase. This leads to selective drug resistances. The risk of an emergence of drug-resistant 
mutants increases primarily with the duration of the therapy. Lamivudine is associated with the 
highest rate of resistance, reaching approximately 70 % by year four of treatment (Lok et al. 2001). 
Combination therapies using lamivudine and PEGylated interferon-α, or a combination of nucleoside 
and nucleotide analogues have been described, but there is only limited data on the efficacy of these 
therapies. 
In the last years, a new class of non-nucleos(t)ide inhibitors has been described. 
Heteroaryldihydropyrimidine and other derivates act as allosteric effectors that deregulate capsid 
assembly (Deres et al. 2003). In vitro, it leads to the formation of aberrant capsid particles and to the 
dissociation of metastable HBV capsids (Stray et al. 2005). In vivo, this mechanism is assumed to 
deplete the pool of core protein available for virion assembly. Alkylated imino sugars, like n-(n-
Nonyl)-deoxygalactonojirimycin, have been shown to possess an antiviral activity on HBV (Mehta et 
al. 2001) by destabilization of HBV capsids or prevention of their maturation (Lu et al. 2003). 
1.4.3. HBV preS-derived lipopeptides as entry inhibitors 
Based on the study of the preS1-requirement for HBV infection, a region encompassing the N-
terminal amino acids 2 to 77 of the L protein has been found to be essential (Le Seyec et al. 1999). 
Another study described an N-terminally myristoylated peptide comprising this region (HBVpreS/2-
78myr), that blocked HBV infection on PHH and HepaRG cells (Gripon et al. 2002). Interestingly, this 
sequence includes epitopes for monoclonal antibodies (e.g., MA18/7 or 5a19) that block the binding 
of HBV particles to PHH (Maeng et al. 2000) and HepG2 (Neurath et al. 1986), and neutralize HBV 
infection on PTH (Glebe et al. 2003). These findings led to the investigation of the ability of preS1 
sequences to inhibit HBV infection. 
HBVpreS/2-48myr has been described as the prototype of inhibitory peptides that block HBV infection 
in vitro and in vivo with high specificity and efficacy (Gripon et al. 2005; Petersen et al. 2008). A study 
towards the pharmacokinetic behavior of this peptide has been described above. As a first-in-class 
HBV entry inhibitor HBVpreS/2-48myr (“Myrcludex B”) is currently being developed for clinical use. 
The thesis presented here will give some insights into pharmodynamic features of Myrcludex B -
derivatives. 
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2. Materials and Methods 
2.1 Materials 
2.1.1. Eukaryotic cells 
2.1.1.1. Cell lines 
Cell line Description Reference 
   
HEK 293-T human embryonic kidney cells, transformed 
with the SV40 large T-antigen 
DuBridge et al., 1987 
HepAD38 stably transfected derivate of HepG2, 
tetracyclin-inducable virus producer cell line 
Ladner et al., 1997 
HepaRG human hepatoma cell line that can be 
differentiated 
Gripon et al., 2002 
HepG2 human hepatoma cell line ATCC# HB-8065  
HuH7 human heptoma cell line JCRB# 0403 
 
2.1.1.2. Primary cells 
 
Cryopreserved hepatocytes 
Species Description Batch Ordering 
number 
Company/ 
Origin 
     
Cynomolgus monkey 
hepatocytes 
Male Cynomolgus Monkey LOT C8 454930 BD Gentest 
 Male Cynomolgus Monkey LOT C10 454930 BD Gentest 
 Male Cynomolgus Monkey LOT JNM M00305 Celsis 
Dog hepatocytes Male Beagle Dog LOT OES M00205 Celsis 
 Male Beagle Dog LOT DXB M00205 Celsis 
Human hepatocytes no information #349 - HepaCULT 
 no information #431 - HepaCULT 
 no information #357 - HepaCULT 
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 no information #636 - HepaCULT 
Pig hepatocytes Male Gottingen Minipig LOT XNG M00615 Celsis 
Rabbit hepatocytes Male New Zealand White Rabbit LOT ()MC F00405 Celsis 
 Female New Zealand White 
Rabbit 
LOT TAH M00405 Celsis 
Rat hepatocytes Male Rat (Sprague Dawley) LOT 06830 454701 BD Gentest 
 Male Rat (Sprague Dawley) LOT 11316 454701 BD Gentest 
Rhesus monkey 
hepatocytes 
Male Rhesus Monkey LOT YUL M00315 Celsis 
Tupaia hepatocytes Female Tupaia Belangerii  PD Dr. J. Petersen, University Hospital 
Hamburg-Eppendorf 
 
Freshly isolated hepatocytes 
Species Description Age Company/ Origin 
 
    
Mouse hepatocytes Female NMRI 52 - 77 days Charles River 
Rat hepatocytes Female Sprague 
Dawley 
8 - 12 weeks Charles River 
Woodchuck 
hepatocytes 
no information no information Prof. Dr. M. Roggendorf,  
University Hospital Essen 
 
2.1.2. Cell culture media 
Description Use Basic medium Supplements 
    
PMH I Attachment medium for PMH Williams E 10 % FCS 
50 U/ ml penicillin 
50 µg/ ml streptomycin 
2 mM L-glutamine 
PMH II Cultivation medium for PMH Williams E As PMH I, without 10 % FCS 
PHH I Attachment medium for PHH Williams E 10 % FCS 
50 U/ ml penicillin 
50 µg/ ml streptomycin 
50 µM hydrocortisone-
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hemisuccinate 
5 µg/ml insuline 
2 mM L-glutamine 
PHH II Cultivation medium for PHH Williams E As PHH I, without 10 % FCS 
PHH II + DMSO Cultivation medium for PHH Williams E As PHH II, additionally  
2 % DMSO 
HepaRG  Cultivation medium for 
HepaRG cells 
Williams E 50 U/ ml penicillin 
50 µg/ ml streptomycin 
50 µM hydrocortisone-
hemisuccinate 
5 µg/ml Insuline 
HepaRG 
diffmed 
Differentiating medium for 
HepaRG cells 
Williams E As HepaRG, additionally 
0.5 - 2 % DMSO 
HepAD38  
    (tet on) 
Cultivation medium for 
HepAD38 
DMEM/F-12 10 % FCS 
50 U/ ml penicillin 
50 µg/ ml streptomycin 
400 µg/ ml G418 
50 µM hydrocortisone-
hemisuccinate 
0.3 µg/ ml tetracycline 
HepAD38  
    (tet off) 
Induction medium for 
HepAD38 virus production 
DMEM/F-12 As HepAD38 tet on, without 
tetracycline 
HepG2 Cultivation medium for HepG2 Williams E 10 % FCS 
50 U/ ml penicillin 
50 µg/ ml streptomycin 
2 mM L-glutamin 
Huh7 
 
Cultivation medium for Huh7 DMEM 10 % FCS 
50 U/ ml penicillin 
50 µg/ ml streptomycin 
2 mM L-glutamin 
Leibovitz’s CO2- independent medium 
without phenol red for live cell 
imaging 
Leiboviz L-15 50 U/ ml penicillin 
50 µg/ ml streptomycin 
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2.1.3. Chemicals and reagents 
Compound Company 
  
Acetic acid Merck 
Acrylamide/ Bisacrylamide (29:1) Serva 
Agarose, UltraPure™ Invitrogen 
Alexa Fluor 488, succinimidyl ester Invitrogen 
Ammonium persulfate (APS) Grüssing 
Ampicillin Sigma 
Atto 565, maleimide ATTO-TEC 
Aqua ad iniectabilia Braun 
Bacto™ agar BD 
Bovine serum albumin (BSA), fraction V, ≥ 98 % Roth 
Bromophenol blue Chroma 
CitiFluor CFPVOH, aqueous poly vinyl alcohol Agar Scientific 
CitiFluor AF100, antifadent-PBS solution Agar Scientific 
Collagenase, type IV, 839 units/ mg Sigma-Aldrich 
DAPI (4’,6’-Dianidin-2-phenylindol) Roche 
Dimethyl sulfoxide (DMSO), for spectroscopy Merck 
Disodium hydrogen phosphate dihydrate (NA2PO4 2H2O) J.T.Baker 
Dithiothreitol (DTT), molecular biology grade Fermentas 
Dulbecco’s modified eagles medium (DMEM) Gibco 
Easycoll Separating Solution, 1.124 g/ ml Biochrom 
Ethanol Riedl-de-Haën 
Ethidium bromide Sigma 
Ethylenediaminetetraacetic acid (EDTA) Roth 
FastPlasmid Mini Kit 5Prime 
Fetal calf serum (FCS) PAA, Biowest 
Glutamine, L- Invitrogen 
Glu-c (V8 protease) Merck 
Glycerine Roth 
Glycin Applichem 
Hydrogen chloride (HCl) Merck 
Hydrocortison-hemisuccinate Sigma 
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Incidin Special Spray Ecolab 
Insulin Sigma 
Isopropyl alcohol AppliChem 
Leibovitz’s medium, L-15 (without phenol red) Gibco 
Loading dye, 6x MBI 
Methanol J.T.Baker 
Megaprime™ DNA labeling system GE Healthcare 
Milk powder Roth 
Orange G Sigma 
Paraformaldehyde (PFA) Sigma 
P32 dCTPs Perkin Elmer 
Phosphate buffered saline (PBS 10x), pH 7.2  Gibco 
Penicillin (5000U/ml), Streptomycin (5000µg/ml) Gibco 
PerfectPrep Endofree Plasmid Maxi Kit 5Prime 
Polyethylenglycol 8000 (PEG) Merck 
Polyethylenimine (PEI) Sigma 
Polyvinylpyrrolidone Merck 
Potassium chloride (KCl) J.T.Baker 
Potassium dihydrogen phosphate (KH2PO4) Gerbu 
Qiagen Midi Plasmid Kit Qiagen 
Qiaquick Gel Extraction Kit Qiagen 
Silver nitrate (AgNO3), 99 % Acros Organics 
Sodium azide (NaN3) Riedel-de-Haën 
Sodium chloride (NaCl) Grüssing 
Sodium citrate Sigma 
Sodium dodecyl sulfate (SDS) Serva 
Sodium hydroxide (NaOH) J.T. Baker 
Standard culture-medium Merck 
Sucrose Roth 
Tetramethylethylenediamine (TEMED) Roth 
T4 Ligase buffer (10 x) New England Biolabs 
Tris(hydroxymethyl)aminomethane (Tris) Roth 
Triton® X-100 Merck 
Trypsin, with or without phenol red Gibco 
Tween® 20 Roth 
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Vectashield® Mounting Medium with DAPI Linaris  
William´s medium E Gibco 
 
2.1.4. Consumables 
Name Company 
  
96-well plate, flexible, Polyvinylchlorid BD Falcon 
Centrifuge Tubes (Ultra- clear, 11x 60 mm) Laborgeräte Beranek 
Cell culture flask (T 75cm2) Corning 
Cell culture plate (12- well) Corning 
Column (Microspin™ G-25) GE Healtcare 
Cover slips Marienfeld GmbH 
Lab-Tek chambered coverglass (8 well) nunc 
Microassay plate (black, clear bottom) Greiner 
µ-dishes (35 mm, high) ibidi 
Nitrocellulose Membrane Schleicher & Schuell 
Nylon-Membrane (positively charged) Roche 
Objective slides Corning, Thermo Scientific 
Pasteur pipettes WU Mainz 
Parafilm Pechiney Plastic Packaging 
Petri dishes Greiner Bio-one 
Pipette tips Star Lab 
Pipette tips filtered Star Lab 
Reaction tubes (1,5 ml, 2 ml) Sarstedt 
Reaction tubes (for AxSYM, 2 ml) Sarstedt 
Reaction tubes (0,2 ml) Biozym 
Serological pipettes (5 ml, 10 ml, 25 ml) Corning 
Tubes (15 ml, 50 ml) Greiner 
Whatman paper Whatman 
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2.1.5. Technical equipment and instruments 
Apparatus Manufacturer 
  
Camera CyberShot DSC S75 Sony 
Centrifuge, Multifuge® 3-SR Heraeus 
Centrifuge, Fresco 21 and Biofuge pico (table top centrifuges) Hereaus, Thermo Scientific 
Centrifuge (J2-21 M/E) Beckman 
Electrophoreses Power Supply   
(EPS 500/400,  EPS 3500) 
Pharmacia 
Monacor 
Electron multiplying charge coupled devices (EM-CCD 
cameras) 
         - C9100-50 
         - ORCA-AG 
 
Hamamatsu 
Hamamatsu 
Flow cytometers 
         - FACS Calibur 
         - FACS Canto II 
 
BD 
BD 
Fraction recovery system Beckman 
Freezer (-80°C) NAPCO 
Fridge/ Freezer (4°C, -20°C) Liebherr 
Gel chambers for SDS -PAGE Amersham Pharmacia 
Glassware Schott 
Heat block (Ori-Block OB-3) Techne 
Hybridization oven (BFED 23) Binder GmbH 
Ice machine (MF-30 AS) Scotsman 
Incubator (37°C, CO2) Heraeus, Thermo scientific 
Incubator shaker Gallenkamp 
Licor Odyssee Licor 
Magnet stirrer IKA 
Microwave Daewoo 
Microscopes 
          - Spinning Disk confocal ERS-FRET on  TE2000 inverted 
          - Total Internal Reflection Fluorescence on Ti inverted 
          - Axiovert 25 
 
Perkin Elmer, Nikon 
Perkin Elmer, Nikon 
Zeiss 
Laminar airflow cabinet Napco, The Baker Company 
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Minifold Dot blot system (96-well) Whatman 
Multichannel Pipette (P200) Eppendorf 
Neubauer Counting Chamber  
          (Improved 0.1 mm, 0.0025 mm2) 
Assistent Germany 
pH-meter (632) Metrohm 
Phosphor-Imager, FX Bio-Rad 
Pipettes (P20, P200, P1000) Gilson 
Pipette (P2) Eppendorf 
Pipettors Brand 
Plates for SDS-PAGE (glass and alumina plates) Amersham Pharmacia 
Printer (P91, for agarose gel pictures) Mitsubishi 
Pump Vaccuubrand 
Scale Kern 
Spectrophotometer (Nanodrop 1000 UV-VIS) Thermo scientific 
Thermomixer comfort Eppendorf 
Transfer chamber (SD Transfer Cell)  Bio-Rad 
Ultracentrifuge (Discovery 90SE) Sorvall 
Ultracentrifuge rotors (SW-60, TH641) Sorvall 
UV-table and lamp M&S Laborgeräte 
Vortexer Neolab 
Water bath Medingen, B. Braun 
 
2.1.6. Special software 
Name Company 
  
CellQuest Pro BD 
CorelDraw Graphics Suite Corel 
FACSDiva BD 
GraphPrism GraphPad 
ImageJ (open source program) 
NIS elements Nikon 
Odyssee Licor 
Photoshop Adobe 
SigmaPlot Systat Software 
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Virtual Dub Open source 
Volocity Perkin Elmer 
Volocity Demo Perkin Elmer 
Quantity One BioRad 
 
2.2 Methods 
2.2.1. Cell culture 
All cell culture works were performed sterile under a laminar flow. 
2.2.1.1. Cultivation of cell lines 
All cell lines were cultivated at 37°C, with a humidity of 95 % and 5 % CO2. 
Experiments utilizing the hepatoma cell lines HepG2 and HuH7, and the cell line 293T were 
performed after passaging these cells in culture no more than 30 times. For passaging, cells were 
detached from the substrate by trypsin treatment, and diluted 10- to 20-fold in new cell culture 
flasks. 
Undifferentiated HepaRG cells were passaged by 5-fold dilution every 2 weeks. To induce 
differentiation, HepaRG cells were seeded at a density of 1.25 x 106 cells/ well (12-well) and 
differentiation was performed as described in Gripon et al. (2002). 
2.2.1.2. Preparation and cultivation of freshly isolated primary hepatocytes 
Primary hepatocytes from mice or rats 
Primary mice or rat hepatocytes were prepared from 52 - 77 days old mice or 8 - 12 weeks old rats, 
respectively. Described here is the isolation of liver cells from mice, numbers or descriptions in 
brackets indicate the respective volumes or instructions for the isolation of hepatocytes from rats. 
NMRI mice (Sprague dawley rats) were killed by cervical dislocation (CO2) and the abdomen was 
opened to expose the liver. A catheter 24G (20G) was carefully inserted into the Vena cava inferior 
and connected to a peristaltic pump. The pump was switched on with a flow rate of 5 - 8 ml/ minute 
(20 ml/ minute) and immediately after starting the pump, the Vena portae was cut to facilitate a 
retrograde perfusion of the liver. The liver was perfused for at least 5 (10) minutes with EGTA-buffer 
and afterwards perfused for additional 5 - 10 (at least 10) minutes with collagenase-buffer. Both 
buffers were pre-warmed in a waterbath to 42°C. After perfusion, the liver was carefully removed 
and transferred to the remaining collagenase-buffer. 
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Under a sterile laminar flow, the liver was suspended in collagenase-buffer by cautious pulling apart 
with sterile tweezers.  The liver capsule and, if necessary, the gall bladder were removed and the 
liver cell suspension was strained through a 100 µm mesh. The cells were collected by centrifugation 
for 5 (10) minutes at 28 x g and 4 °C. The cell pellet was resuspended in 19 (28) ml Percoll® solution 
with a density of 1.063 g/ ml, and centrifuged for 10 (20) minutes at 50 x g at 4°C without brake. This 
step allowed the separation of parenchymal from non-parenchymal cells. Due to the bigger size of 
the parenchymal cells, the hepatocytes sedimented more quickly compared to other liver cells. 
Percoll® strengthened this effect. After centrifugation, the supernatant was removed and the 
resulting pellet, containing purified hepatocytes, was washed with cold William’s E medium to get rid 
of remaining Percoll®. Cells were re-collected by centrifugation for 5 (10) minutes at 28 x g and 4 °C.  
If the cells were destined for peptide binding studies in solution, the pellet was resuspended in the 
respective peptide binding solution, i.e. PMH II, PHH II or HepaRG Diffmed. The final cell suspension 
was checked for viability and the cell number by trypan blue exclusion. 
If the cells were destined for microscopical analysis, the hepatocytes were seeded on cover slips that 
had been coated with 0.1 mg/ ml rat tail collagen over night. Seeding was performed in the 
respective attachment-medium, i.e. PMH I or PHH I, using the respective densities listed in table 
below. 
 
Buffers  
  
EGTA perfusion buffer 2 mM L-Glutamine, 0.5 % Glucose, 25 mM HEPES, 2 mM EGTA, pH7.4 
 diluted in PBS, sterile 
Collagenase perfusion buffer 2 mM Glutamine, 0.5 % Glucose, 25 mM HEPES, 3 mM CaCl2, 3 mg/ ml 
Collagenase type IV 
 diluted in plain Williams E, sterile filtered 
  
 
Primary human hepatocytes 
PHH were obtained by Thomas Weiss, University Hospital Regensburg. The cells were isolated and 
cultivated in serum-free medium as previously described (Weiss et al. 2003). Tissue samples from 
liver resections were obtained from patients undergoing partial hepatectomy for metastatic liver 
tumors of colorectal cancer. Experimental procedures were performed according to the guidelines of 
the charitable state controlled foundation HTCR (Human Tissue and Cell Research), with the 
informed patient's consent approved by the local ethical committee of the University of Regensburg. 
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The PHH were shipped on ice in “cell maintenance medium”. Upon arrival, the cells were diluted with 
cold PHH I and collected by centrifugation for 3 minutes at 100 x g, 4°C. The cell pellet was 
resuspended in PHH I (or PHH II for experiments with cells in solution) and cell viability and number 
was determined by trypan blue exclusion.  Cells were seeded on collagen-coated coverslips with the 
density given in the table below. 
 
Cell type Seeding density (cells/ cm2) Number of cells/ well (12-well plate) 
   
PMH 0.5 x 105 0.2 x 106 
PRH 0.5 x 105 0.2 x 106 
PHH 0.15 x 106 0.58 x 106 
 
2.2.1.3. Thawing and handling of cryopreserved hepatocytes 
Cryopreserved hepatocytes were delivered frozen in liquid nitrogen or, for PHH and PTH, on dry ice. 
After arrival, the cells were thawed quickly in a waterbath at 37°C and diluted in 9 ml cold PMH II 
medium. To recover cells and to remove toxic substances from the freezing medium, cells were 
centrifuged for 3 minutes at 100 x g and 4°C (or room temperature). The cell pellet was carefully 
resuspended in PMH II (or a respective medium), and the number and viability of the cells was 
determined by trypan blue exclusion. 
2.2.1.4. HBV infection of HepaRG cells 
For an infection with HBV, HepaRG cells were seeded in a 12-well cell culture dish. If not indicated 
differently, the infection was performed with a multiplicity of genome equivalents (MGE) of 1 x 104 
GE/ cell. Cells were inoculated with PEG-precipitated stock virus (100-fold concentrated HepAD38 
supernatant) in presence of 4 % PEG for approximately 16 hours at 37°C. Subsequently, the virus 
solution was removed, cells were washed thoroughly, and further incubated with fresh medium. The 
supernatant was collected from day 4 to 7, and day 7 to 12 after infection, and was analyzed for 
HBeAg and/ or HBsAg as markers for infection. HBeAg and HBsAg were measured by the commercial 
enzyme-linked immunoabsorbant assays (ELISA) AxSYM (formerly Architect) and Advia Centaur, 
according to the manufacturer’s protocol. 
2.2.2. Peptide binding assays 
2.2.2.1. Peptide synthesis 
All peptides were synthesized by Alexa Schieck and Thomas Müller (AG Mier, Department of Nuclear 
Medicine) by solid phase peptide synthesis employing the Fmoc/tBu strategy with HBTU/DIPEA 
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activation in an Applied Biosystems 433A peptide synthesizer. Fluorescein isothiocyanate was 
coupled to the ε-amino group of an artificially introduced lysine at position 49. Alternatively, 
Atto565-maleimide was linked to an introduced cysteine at position 49. Preparative reversed phase 
high performance liquid chromatography was carried out using C-18 columns and applying a linear 
gradient from 100 % water to 100 % acetonitrile in 0.1 % trifluoroacetic acid. Preparations were 
analyzed using a Merck Chromolith® Performance RP-18e column (100 - 4.6 mm; flow rate of 4 ml/ 
min) and purified by Chromolith® SemiPrep RP-18e column (100 - 10 mm; flow rate of 10 ml/ min). 
The identity of the peptides was controlled by mass spectrometry.  
2.2.2.2. Peptide binding to adherent cell culture for microscopy 
100 µM stock solutions of the respective peptides in 2 % DMSO were diluted to the appropriate final 
concentration in medium without FCS (if not indicated differently). Cells that were grown on cover 
slips were incubated with 200 nM of the respective peptide for at least 1 hour at 37°C. After 
incubation, cells were washed thoroughly with PBS and fixed with 4 % PFA for 30 minutes at room 
temperature. Before embedding, the PFA was removed by washing the cells twice with PBS. Cover 
slips were mounted on object slides using mounting medium with DAPI (Vecta Shield Hart Set 
Mounting Medium with DAPI) or without DAPI (Citifluor AF-100) and stored at 4°C until performance 
of microscopy. 
2.2.2.3. Staining of the cells with Phalloidin-Alexa546 or Phalloidin-Alexa565 
In order to visualize the actin cytoskeleton of hepatocytes or HepaRG cells, cells on cover slips were 
fixed and permeabilized with 0.1 % Triton X-100 in PBS for 20 minutes. Phalloidin-Alexa546/ -
Alexa565 was added at 0.05 mg/ ml in 0.1 % Triton X-100/ PBS for 15 minutes in the dark, washed 
with PBS and mounted on object slides as described above. 
2.2.2.4. Destruction of the actin cytoskeleton by cytochalasin D 
To interfere with actin polymerization, cells grown on cover slips were incubated with 20 or 40 µM 
cytochalasin D diluted in 500 µl PMH II for 1 hour at 37°C. Subsequently, the drug was removed, cells 
were washed carefully with warm PMH II and supplied with 200 nM HBVpreS/2-48myr-K-FITC for 1 
hour at 37°C. After peptide incubation, cells were washed and fixed as described above. 
2.2.2.5. Peptide binding to cells in solution for flow cytometry 
For the flow cytometric analysis, freshly isolated or thawed cryopreserved hepatocytes were 
aliquoted à 0.4 - 0.5 x 106 cells in Eppendorf cups or FACS vials. The cells were either pelleted for 3 
minutes at 100 x g and 4°C, and the pellet was resuspended in an appropriate peptide dilution, 
directly supplied with pre-diluted peptide. Under frequent mixing (to avoid sedimentation), the 
Materials and Methods  25 
hepatocytes were incubated at room temperature for 30 minutes in the dark. The cells were then 
collected by centrifugation for 3 minutes, 100 x g, and washed 5 times with 1 ml PBS. The washed 
cells were resuspended in 500 µl PBS and fluorescence was immediately measured by flow 
cytometry. 
Flow cytometry of cryopreserved hepatocytes was performed on a FACS Calibur (BD) and the 
software CellQuest Pro (BD). Freshly isolated hepatocytes were analyzed at a FACS canto II (BD) using 
the software FACS Diva (BD). 
In order to check cell viability, every experiment was controlled by staining the hepatocytes with 
propidium iodide (PI) in parallel. Therefore, an aliquot of 0.4 x 106 cells/ ml was incubated with PI, 
diluted in PMH II medium to a final concentration of 10 µM. The cells were incubated for 30 minutes 
under frequent mixing at room temperature in the dark. Alternatively, a control stain using Hoechst 
33342 dye at a concentration of 0.01 mg/ ml was performed. The dye, entering live cells and binding 
to DNA, was added directly to the samples shortly before measurement. 
2.2.2.6. Competition assays using HBVpreS/2-48myr, heparin or suramin 
Competition of binding with unlabeled peptide was performed by co-incubation of HBVpreS/2-48myr-
K-FITC with a 100-fold excess of HBVpreS/2-48myr, or HBVpreS/2-48myr(D11,13) as a control. Cells 
were exposed to a mixture of both, fluorescently labeled and non-fluorescent peptide. (An exception 
is the experiment with hepatocytes from different species. Here, the competing agents were pre-
incubated with the cells for 5 minutes before addition of the fluorescent peptide.) For fluorescence 
microscopy, 200 nM HBVpreS/2-48myr-K-FITC were co-incubated with a 50- fold excess (10 µM) of the 
consensus sequence chHBVpreS/2-48myr. All cells were incubated for 0.5 - 1 hour at 37°C. 
For competition experiments with heparin and suramin, heparin (600 µg/ ml) and suramin (200 µg/ 
ml) were mixed with 200 nM HBVpreS/2-48myr-K-FITC. The mixture was incubated for 30 minutes at 
20°C with frequent mixing. Subsequently, the mixture was incubated with cells grown on cover slips 
for 1 hour at 37°C, washed and fixed. 
2.2.2.7. Protease digestion of surface proteins 
Protease treatment of freshly isolated PMH was performed in serum-free PMH II. Glu-c was 
incubated with 0.5 x 106 cells for 30 minutes at 37 °C at a final concentration of 40 µg/ ml and 80 µg/ 
ml, respectively. Trypsin was incubated in the same way at 0.005 % or 0.015 %. 
After incubation the cells were washed excessively (5 times with 1 ml PBS) and HBVpreS/2-48myr-K-
FITC was added at a concentration of 200 nM in PMH II. 
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2.2.2.8. Quantification of HBVpreS/2-48myr on cells by HPLC-MS/MS 
To determine the fraction HBVpreS/2-48myr bound to PRH, PHH and HepaRG cells, the samples were 
incubated with a dilution series of the peptide in HepaRG Diffmed and subsequently shipped to 
Prolytic GmbH in order to perform HPLC-MS/MS. 
PRH were freshly prepared and PHH were derived from cryopreserved samples. These primary 
hepatocytes were aliquoted à 0.4 x 106 cells/ vial, pelleted by centrifugation for 3 minutes, 100 x g, 
and the cell pellet was resuspended in serial dilutions containing 0 to 1000 nM HBVpreS/2-48myr 
(Myrcludex B, produced by Bachem) in duplicates. The suspensions were incubated for 30 minutes at 
37°C under frequent mixing. Subsequently, the cells were pelleted by centrifugation for 3 minutes, 
100 x g, and washed 3 times. 
HepaRG cells were bought from Biopredic as differentiated cells in a 24 well plate. After arrival, the 
cells were treated according to the manufacturer’s instructions, applying recovery-medium over 
night and further cultivate the cells with maintenance-medium. The cells were then incubated with 
serial dilutions containing 0 to 1000 nM HBVpreS/2-48myr (Myrcludex B, produced by Bachem) in 
duplicates for 30 minutes at 37°C. Afterwards, the cells were washed 3 times with PBS, scraped of 
the wells, transferred to Eppendorf cups and pelleted. 
From all final cell pellets, the supernatant was removed as complete as possible and the cells were 
weighed, frozen in liquid nitrogen, and shipped on dry ice to Prolytic GmbH. 
2.2.3. Production of fluorescently labeled HBV 
2.2.3.1. Preparation of HBV-Alexa488 
In order to produce fluorescently labeled particles, HBV was purified from HepAD38 cell culture 
supernatant by heparin affinity chromatography and gel filtration as described by Caroline Gähler, 
diploma thesis, based on a buffering system with PBS. The purified virus was used for the labeling 
reaction with Alexa488-succinimidyl ester. 
Therefore, a stock solution of Alexa488- succinimidyl ester (5 mg/ ml in DMSO) was diluted at a final 
concentration of 0.04 mg/ ml with purified virus. The reaction was carried out at room temperature, 
rotating at 20 rpm, and was stopped after 1 hour by addition of TN buffer (20 mM Tris, 140 mM 
NaCl). Unbound dye was quenched by the primary amines contained in the TN buffer, and removed 
by heparin affinity chromatography as described by Caroline Gähler, diploma thesis. The virus peak 
fractions were further purified and concentrated by sucrose-density gradient ultracentrifugation, 
applying a gradient from 15 % to 60 % sucrose (w/w in PBS). Ultracentrifugation was performed with 
40 000 x g for 20 hours at 20°C. After ultracentrifugation, the gradient was checked by UV light for 
fluorescent bands, and the gradient was fractionated collecting ~ 0.5 ml fractions. 
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2.2.3.2. Biochemical analysis of HBV-Alexa488 
The fractions from the sucrose-density gradient were analyzed by DNA dot blot, measurement of 
Alexa488- fluorescence, polyacrylamide gel electorphoresis and subsequent western blotting or silver 
staining. 
2.2.3.3. Quantification of HBV-DNA (DNA-dot blot) 
In order to quantify the DNA content of the sucrose-density fractions, samples (5 - 20 µl) of the 
fractions were spotted directly on PBS- moisturized nylon membrane (positively charged, Roche) 
using a 96-well Minifold dot blot chamber (Schleicher & Schuell). As a standard, a dilution series of 
the HBV genome-containing plasmid pCHT-9/3091 (5 x 109, 1 x 109, 2 x 108, 4 x 107, 8 x 106 and 1.6 x 
106 molecules per spot) was included. After application, the membrane was washed once with PBS, 
dried and soaked 2 x 1.5 minutes in soak I buffer in order to denaturate the DNA. For neutralization, 
the membrane was soaked 4 x 1 minute using soak II buffer. The DNA was then fixed by incubating 
the membrane for 30 minutes at 90°C. 
To hybridize a HBV-specific, radioactively labeled DNA- probe, the membrane was incubated with 
hybridization mixture at 68°C, rotating over night. The DNA-probe was made using the MegaprimeTM 
DNA Labeling Systems Kit from GE Healthcare, according to the manufacturer’s protocol. 
Subsequently, the membrane was washed with DNA dot-blot washing buffer, rotating for 2 x 15 
minutes at 68°C and at room temperature. The membrane then was used to expose a BAS-MP (Fuji) 
film for at least 10 hours. The signal was read and quantified by a Phosphor-Imager FX and the 
software Quantity One (BioRad). 
 
Buffer/Solution Composition 
  
Soak I: 0.5 M NaOH, 1.5 M NaCl 
Soak II: 0.5 M Tris pH 7.4, 3 M NaCl 
Hybridization mix: 6x SSC, 5x Denhardts, 0.5 % SDS, 10 µg/ ml calf thymus DNA 
Wash buffer: 1x SSC, 0.5 % SDS 
DNA-probe: 5 µl DNA (pCH-9/3091), 5 µl random-primer, 16 µl H2O  5 min, 95 °C 
 non-radioactive dATP, dTTP, dGTP, 4 µl each, 
5 µl 10x reaction buffer, 5 µl 32αP-dCTP, 2 µl Klenow polymerase 
 20 min, 37°C 
   
2.2.3.4. Quantification of fluorescence 
To measure fluorescence of the sucrose density fractions, samples (5 - 20 µl) of the fractions were 
diluted with PBS to a final volume of 200 µl in black 96-well plates with a transparent, flat bottom. 
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The fluorescence was analyzed using a Tecan Safire plate fluorometer and the software XLFUOR V4.5, 
with an excitation wave length of 485 nm and detecting fluorescence emission at 520 nm, both with 
a bandwidth of 5 nm. The optimal gain was calculated by means of the most fluorescent well. 
2.2.3.5. Analytical detection of proteins 
Analytical protein electrophoresis was performed under denaturing conditions using SDS-PAGE 
described in Laemmli et al. (1970). 
 
Buffer Composition 
  
1x Running buffer: 0.025 M Tris, 0.086 M Glycin, 0.0035 M SDS 
4x Stacking gel buffer: 0.05 M Tris/HCl pH 8.8, 0.4 % SDS, 0.01 % NaN3 
4x Separating gel buffer: 1.5 M Tris/HCl pH 8.8, 0.4 % SDS, 0.01 % NaN3 
2x Loading buffer: 200 mM Tris/HCl pH 6.8, 6 % SDS, 20 % Glycerol, 10 % DTT,  
0.1 mg/ ml Bromphenolblue, 0.1 mg/ ml Orange-G,  
 
 
Solution 4 % Stacking gel 12.5 % Separating gel 
   
H2O 11 ml 17.5 ml 
4x Stacking gel buffer 5 ml - 
4x Separating gel buffer - 12.5 ml 
Bis-acrylamide 4 ml 20 ml 
Temed 10 µl 25 µl 
Ammoniumpersulfate “Spatelspitze” “Spatelspitze” 
 20 ml 50 ml 
 
2.2.3.5.1. Western Blot analysis 
For detection by Western Blotting, proteins were transferred on a nitrocellulose transfer membrane 
(0.45 µm pore size, Whatman) using a semi-dry blotting chamber (BioRad). Subsequently, the 
membrane was blocked in 10 % milk powder in TBST and antibodies were applied in 2 % milk powder 
in the respective concentrations. Primary antibodies were incubated on a shaking device over night 
at 4°C, fluorescently labeled secondary antibodies for 1 hour at room temperature in the dark and in 
absence of Tween-20. After washing, fluorescence of the secondary antibodies was detected by a 
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Licor Odyssey and the software Odyssey 2.0, using an excitation wavelength of 700 nm and/ or 800 
nm. 
Buffer Composition 
  
1x TBST: 0.14 M NaCl, 0.02 M Tris, 0.05 % Tween-20, pH 8 
Schäffer-Nielsen transfer buffer: 0.05 M Tris, 0.02 M Glycin, 0.04 % SDS, 10 % methanol, pH 9 - 9.4 
 
2.2.3.5.2. Silver gel analysis 
To detect total protein content, polyacrylamide gels were fixed after electrophoresis with fix I over 
night, fix II for 30 minutes and fix III for 2 x 15 minutes. Impregnation of the gels was performed for 2 
minutes using the impregnation solution, and subsequently proteins were stained by a solution 
containing AgNO3. To visualize the protein-silver precipitates, the gel was incubated with developing 
solution until proteins were well visible. The reaction was stopped with the stopping solution for 
approximately 1 minute and the gel was washed, and stored in H2O. 
Solution Composition Protocol 
   
Fix I: 50 % Methanol, 12 % Acetic acid  1 h or o/n 
Fix II: 10 % Ethanol, 5 % Acetic acid  30 min 
Fix III: 10 % Ethanol  2 x 15 min 
Solution A: 0,02 % Sodiumthiosulfate,  
0.02 % Formaldehyde 
 2 min 
Solution B: 0.2 % Silvernitrate, 0.02 % Formaldehyde  12 min (dark) 
Solution C: 3 % Sodium carbonate,  
0.02 % Formaldehyde,  
0.0003 % Sodiumthiosulfate 
 development 
Stopping solution: 3 % Acetic acid  
   
2.2.4. Microscopy 
2.2.4.1. Spinning disk confocal microscopy 
Fixed samples were analyzed by spinning disk confocal microscopy, using a Perkin Elmer spinning disk 
confocal ERS-FRET on Nikon TE2000 inverted microscope, with a Hamamatsu C9100-50 camera and 
the software Volocity 5.2 (Perkin Elmer). Images were taken with a 100x objective (Planapo NA 1.4, 
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oil) or 60x objective (Planapo NA 1.2, water immersion). Acquisition times were adjusted to the 
respective fluorescent signal, but were not changed within an experiment. Most images were taken 
with a laser power of 100 %. 
2.2.4.2. Fluorescence recovery after photobleaching 
PMH were grown on collagen-coated LabTek chamber slides (8- chambered) and incubated for 1 
hour at 37°C with 200 nM HBVpreS/2-48myr-C-Atto565. As a control, PMH were stained with 5 µl/ 
well DiI (Molecular Probes) for 30 minutes at 37°C. After incubation, the cells were washed with PBS 
and supplied with fresh medium (Leiboviz L-15, without phenol red). 
Fluorescence recovery after photobleaching was measured with the hard- and software of the 
spinning disk confocal microscope described above. Images were taken with a 60x objective (Planapo 
NA 1.2, water immersion) and bleaching was performed using an UltraVIEW PK Device as bleaching 
device. Images pre bleaching were captured for 4 seconds at a rate of 2 timepoints per second, 
recovery images were taken for 30 seconds at the same frame rate. The time lapse was acquired 
using a 568 nm laser as excitation. 
2.2.4.3. Total internal reflection fluorescence (TIRF) microscopy 
TIRF was performed on a Nikon Total Internal Reflection Fluorescence (TIRF) on Ti inverted 
microscope with Nikon Perfect Focus System, using a 100x TIRF objective. Pictures were taken with a 
Hamamatsu EM-CCD camera. 
2.2.4.4. Measurement of fluorescence on digital images 
Fluorescence intensities in digital images were measured using the software ImageJ. Therefore, 
circular regions of the same size were measured with at least 10 measurements per frame in at least 
5 different pictures. The mean fluorescence in the selections was used to calculate an average value 
that directly was used to plot the data.  
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3. Visualization and characterization of the HBV preS1-receptor interaction with 
fluorescently labeled ligands 
3.1 Fluorescently labeled HBVpreS/2-48myr lipopeptides 
HBVpreS/2-48myr has been described to specifically and efficiently inhibit HBV infection in vivo and in 
vitro. Infection inhibition is achieved by an interference with viral entry, most probably through the 
interaction with a specific HBV-receptor. Due to highly similar requirements for their functionality, 
HBV and HBVpreS/2-48myr-peptides are assumed to address a common factor on hepatocytes. The 
peptides therefore provide a powerful tool to analyze receptor binding.  
In order to characterize the interaction of HBVpreS/2-48myr with its receptor, a set of fluorescently 
labeled HBVpreS/2-48myr derivatives was synthesized and visualized. Peptide sequences are based on 
previous findings, that demonstrated a high inhibitory activity of HBVpreS/2-48myr, lacking inhibitory 
activity of HBVpreS/2-48myr(D11,13) and an approximately 1000-fold reduced activity of HBVpreS/1-
48 (Schulze et al. 2010).  An overview about the peptides that have been synthesized is shown in 
Figure 5. 
 
 
Figure 5: Fluorescently labeled HBVpreS/2-48myr derivates. Schematic presentation of the wild type peptide 
HBVpreS/2-48myr-K-FITC (1), comprising amino acids 2 to 48 of the HBV L-protein, the N-terminal myristoylation 
and a fluorescein isothiocyanate (FITC) moiety. The mutant peptide HBVpreS/2-48myr(D11,13)-K-FITC, in which 
amino acids 11 and 13 are replaced by D-isomers is depicted in (2), and (3) shows the non-myristoylated variant 
HBVpreS/1-48-K-FITC. Peptides (1) and (2) were additionally labeled with Atto565 (see middle sequences). 
Experiments that made use of FITC-labeled peptides derived from the genotype D (lower three sequences) are 
indicated in the following. The essential region is defined by vertical bars and amino acid positions are 
indicated by numbers. 
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3.1.1. Production and characterization of fluorescently labeled HBV preS1-lipopeptides 
HBVpreS/2-48myr-K-FITC 
The selective coupling of fluoresceine isothiocyanine (FITC) to a lysine at position 49 during synthesis 
ensured an equimolar ratio of one fluorochrome per peptide molecule. This was important in order 
to conduct comparative binding analysis of a set of peptides. 
The purity of every peptide preparation was controlled by analytical HPLC. As shown in the overlay of 
HPLC profiles from HBVpreS/2-48myr-K-FITC, HBVpreS/2-48myr(D11,13)-K-FITC and HBVpreS/1-48-K-
FITC, peptides appeared as a sharp peak without significant impurities (Figure 6). For further analysis 
mass spectrometry was performed. All peptides matched the theoretical molecular weight (Mr 
expected) of the respective molecule, with a maximal aberration of 0.5 Da being less than half of the 
mass of a hydrogen atom (1H). 
 
 
Figure 6: Purity of the peptide preparations. (A) The purity of the synthesized peptides was controlled by 
analytical HPLC. Depicted are exemplary preparations of three different peptides, indicated in green, red and 
orange. (B) The peptide preparations were checked by mass spectrometry. Expected and identified relative 
molecular masses (Mr) are given as numbers (Da). Peptide names were shortened by deletion of the prefix 
“HBVpreS/”. ch2-48 = sequence of the genotype D. All other sequences are derived from genotype C. 
HBVpreS/2-48myr-C-Atto565 
Since FITC is not suited for live-cell microscopy due to its high photosensitivity, a second batch of 
peptides was synthesized and labeled with the more bleaching-resistant fluorophore Atto565. It was 
coupled to an N-terminal cystein (C49) post synthesis. The control of the purity by analytical HPLC 
(data not shown) and the molecular weight by mass spectrometry (see Figure 6B) indicated the 
presence of the product HBVpreS/2-48myr-C-Atto565. 
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3.1.2. Validation of peptide-functionality by infection inhibition experiments 
To test whether the addition of C-terminally coupled fluorophores interferes with the inhibitory 
characteristics of HBVpreS/2-48myr, infection inhibition experiments have been performed on PHH 
and HepaRG cells. 
An exemplary infection inhibition on PHH is shown in Figure 7. Similar to the unlabeled HBVpreS/2-
48myr, the presence of 250 nM HBVpreS/2-48myr-K-FITC during virus inoculation led to a complete 
inhibition of infection. This demonstrated a functionality of the FITC-labeled peptide. As expected, 
HBVpreS/2-48myr(D11,13)-K-FITC did not inhibit infection, and HBVpreS/1-48-K-FITC exhibited a weak, 
but negligible inhibitory activity. 
Quantitative experiments comparing the effectiveness of HBVpreS/2-48myr and its fluorescently 
labeled derivate have not been performed. 
 
 
Figure 7: Inhibitory functionality of HBVpreS/2-48myr-K-FITC. PHH were infected in duplicates with HBV in 
absence (uncompeted) or presence of 250 nM of the respective peptides. HBeAg as marker for infection was 
measured in the supernatant collected from day 8 to 13. Peptide names were shortened as indicated in Fig. 6. 
3.2 Visualization of HBVpreS/2-48myr-K-FITC binding to hepatocytes 
Despite the detailed knowledge about sequence requirements, the mechanism of action and cellular 
interaction partners of HBVpreS/2-48myr are not known. Since it has been shown that a cellular factor 
is addressed by the peptide (Gripon et al. 2005), this work aimed to visualize and characterize this 
interaction. Following the fate of HBVpreS/2-48myr-K-FITC after exposure to cells might allow 
conclusions about the localization of a preS1-receptor, the prerequisites for its expression, and the 
kinetics and dynamics of the preS1-receptor interaction. 
Results  34 
3.2.1. HBVpreS/2-48myr binds to the plasma membrane of HBV-susceptible hepatocytes in a highly 
sequence- and myristoylation-specific manner 
To test whether a specific interaction of HBVpreS/2-48myr-K-FITC with HBV-susceptible cells can be 
detected, binding studies were performed using the set of peptides described above. 
When PHH were incubated with HBVpreS/2-48myr-K-FITC, a fluorescent staining of the plasma 
membrane was observed by spinning disk confocal microscopy (Figure 8). In contrast, the 
myristoylated mutant peptide HBVpreS/2-48myr(D11,13)-K-FITC did not bind to a significant extent at 
the concentration used here. Neither, binding could be detected using the non-myristoylated 
HBVpreS/1-48-K-FITC. Both demonstrated the high specificity of binding, since only minor changes of 
the peptide sequence (amino acids L-11, 13 to D-11, 13) or the removal of the myristoylation 
resulted in a complete loss of binding. This entirely reflected the respective inhibitory potential of 
these peptides (Figure 7), and demonstrated that the inactivity of the mutant and non-myristoylated 
peptide results from their inability to bind a specific receptor on the surface of PHH. 
As seen in Figure 8A, the same sequence- and myristoylation-dependent binding phenotype was 
observed on PTH and HepaRG cells. It is to mention, that HepaRG cells in general showed a relatively 
weak peptide signal that was difficult to detect. Also, microscopy was hampered by highly 
fluorescent structures on the cell surface of these cells when incubated with a myristoylated FITC-
labeled peptide. These structures probably were a consequence of an unspecific, lipid-mediated 
binding of acylated peptides, since they were not present after incubation with HBVpreS/1-48-K-FITC.  
The insular presence of these highly fluorescent spots, and the weakness of the membrane staining 
after HBVpreS/2-48myr-K-FITC incubation, disqualified HepaRG cells as a suitable model for 
quantitative microscopic binding studies. 
The autofluorescence of primary hepatocytes was also relatively bright. But since dot-like 
autofluorescence was almost exclusively located in the perinuclear region, it did not interfere with 
the observation of a peptide-mediated plasma membrane staining. Hepatocytes are known for a 
bright autofluorescence that can be derived from molecules like lipofuscines, flavines or porphyrines. 
These fluoresce due to their molecular structure, and typically are expressed in metabolizing cells. 
To reassess these results by an alternative assay, flow cytometry was performed with primary 
hepatocytes. Therefore, cryo-preserved PHH were incubated with the set of FITC-labeled peptides in 
suspension, and fluorescence was measured. Indeed, the same binding phenotype was observed. 
Only after incubation with HBVpreS/2-48myr-K-FITC, PHH showed an approximately 10-fold higher 
cell-associated fluorescence, compared to the unstained control (see Figure 8C). In contrast, 
HBVpreS/2-48myr(D11,13)-K-FITC showed a slight background binding that was attributed to an 
unspecific myrisoylation-dependent interaction. Incubation with HBVpreS/1-48-K-FITC did not result 
in a detectable signal. 
Results  35 
 
 
Figure 8: Specific binding of HBVpreS/2-48myr-K-FITC to HBV-susceptible cells. (A) PHH, HepaRG and PTH were 
grown on cover slips, incubated with 200 nM of the indicated peptides and fixed. A mock-incubated control 
showing the autofluorescence of these cells is depicted on the left (without peptide). FITC-fluorescence could 
be seen on the plasma membrane (green), nuclei were stained with DAPI (blue). Images were obtained by 
spinning disk confocal microsocopy with a 600x magnification. (B) PHH were incubated with the set of peptides 
at 200 nM in suspension, washed, and cell-associate fluorescence was measured by flow cytometry. The gate 
shown in red was set on PI-negative cells of homogeneous size and granularity. (C) Binding of HBVpreS/2-48myr-
K-FITC (red line) was detected by an approximately 10-fold higher fluorescence of the population, compared to 
the unstained control (filled gray). The mutant peptide (black line) showed slight background binding. (D) 
Binding of HBVpreS/2-48myr-K-FITC could be competed with 20 µM HBVpreS/2-48myr (red dotted line), but not 
with HBVpreS/2-48myr(D11,13) (black dotted line). Autofluorescence of the cells is shown in gray, filled. Peptide 
names were shortened as indicated in Fig. 6. 
 
Results  36 
The high specificity of binding could additionally be demonstrated by competition experiments. Using 
a 100-fold excess of unlabeled HBVpreS/2-48myr, binding of HBVpreS/2-48myr-K-FITC could be reduced 
to background levels (Figure 8D). In contrast, an excess of HBVpreS/2-48myr(D11,13) had no effect. 
This demonstrated that HBVpreS/2-48myr and its labeled derivate HBVpreS/2-48myr-K-FITC address the 
same factor on the plasma membrane, and that even at a 100-fold excess (20 µM) the mutant 
peptide HBVpreS/2-48myr(D11,13) did not show competitive activity. 
3.2.2. Specific binding of HBVpreS/2-48myr-K-FITC is not restricted to HBV-susceptible cells 
Based on in vivo biodistribution studies in mice and rats that showed a sequence- and myristoylation-
specific liver accumulation of iodinated HBVpreS/2-48myr-YI131 (see Figure 3, Alexa Schieck, diploma 
thesis), primary hepatocytes from mice (PMH) and rats (PRH) were tested in vitro for binding of 
HBVpreS/2-48myr-K-FITC. 
Despite being non-susceptible to HBV infection, both, PMH and PRH, specifically bound HBVpreS/2-
48myr-K-FITC as depicted in the confocal images shown in Figure 9A. Consistent with the previous 
findings on HBV-susceptible cells, no binding was observed after incubation with HBVpreS/2-
48myr(D11,13)-K-FITC or HBVpreS/1-48-K-FITC. In addition, this correlated also with the sequence- 
and acylation-dependency of the liver tropism. 
These results were confirmed by flow cytometry as seen in Figure 9B-D. The high specificity of 
binding could again be demonstrated by competition experiments as described above. An excess of 
unlabeled HBVpreS/2-48myr resulted in a reduction of HBVpreS/2-48myr-K-FITC binding to background 
levels, whereas HBVpreS/2-48myr(D11,13) had no effect. These observations supported the 
assumption of the presence of a specific HBVpreS1-receptor on hepatocytes of even non-susceptible 
mice and rats. 
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Figure 9: Specific binding of HBVpreS/2-48myr to primary rodent hepatocytes. (A) Primary hepatocytes from 
mouse (PMH) and rat (PRH), cultured on cover slips, were incubated with 200 nM HBVpreS/2-48myr-K-FITC and 
the respective derivates, washed and fixed. Plasma membrane-bound fluorescence was documented by 
spinning disk confocal microscopy with a 600x magnification. Autofluorescence is shown on the left (without 
peptide). (B) PMH were incubated with the set of peptides at 200 nM in suspension, washed, and cell-
associated fluorescence was measured by flow cytometry. The gate shown in dark grey was set on PI-negative 
cells of homogeneous size and granularity. (C) Binding of HBVpreS/2-48myr-K-FITC (solid line) was detected by 
an approximately 10-fold higher fluorescence of the population, compared to the unstained control (light gray, 
filled). The mutant peptide (dotted line) showed slight background binding. (D) Binding of HBVpreS/2-48myr-K-
FITC (dotted line) could be competed with 20 µM HBVpreS/2-48myr (solid line), but not with HBVpreS/2-
48myr(D11,13) (dark grey, filled). Autofluorescence of the cells is shown in light gray, filled. Peptide names were 
shortened as indicated in Fig. 6. 
Based on these findings, a whole set of primary hepatocytes from different species was tested for 
specific binding of HBVpreS/2-48myr-K-FITC. Therefore, flow cytometry was performed with 
cryopreserved hepatocytes from rats, rabbits, dogs, humans, cynomolgus monkeys, rhesus monkeys 
and pigs that were incubated with HBVpreS/2-48myr and variants thereof. None of these species, 
except humans, has been shown to be susceptible to HBV infection. 
Surprisingly, we found specific binding of HBVpreS/2-48myr-K-FITC to some, but not all species. 
Binding was detected on hepatocytes from rats, rabbits, dogs, and humans, but not on hepatocytes  
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Figure 10: Species-specific binding of HBVpreS/2-48myr-K-FITC to primary hepatocytes. Cryopreserved primary 
hepatocytes from rat, rabbit, dog, human, cynomolgus monkey, rhesus monkey and pig were incubated with 
200 nM HBVpreS/2-48myr-K-FITC and the indicated control peptides. Competition of binding was performed 
with a 100-fold excess (20 µM) of the respective unlabeled wild type or mutant peptide. Cell-associated 
fluorescence was measured by flow cytometry. Hepatocytes were obtained from n = 3 (human, cynomolgus), n 
= 2 (rat, rabbit, dog) or n = 1 (rhesus, pig) liver preparations. (A) represents the mean fluorescence intensities of 
the different samples. (B) shows the normalized values for the specificity of binding. The signal of HBVpreS/2-
48myr-K-FITC for each species was divided by the respective signal intensity of HBVpreS/2-48myr(D11,13)-K-FITC. 
The resulting factor was subtracted by 1. (C) Freshly isolated primary woodchuck hepatocytes were incubated 
with 200 nM of the respective peptides as described in A. Depicted are the histograms of the distribution of 
fluorescence within the gated cell population. Gate P3 indicated the percentage of fluorescence-positive cells, 
zero was defined using untreated cells (w/o peptide). 
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from pigs, cynomolgus or rhesus monkeys (Figure 10A). This indicated that a specific preS1-receptor 
is expressed by hepatocytes from some, but not all non-susceptible species.  
Interestingly, the fluorescence intensities after peptide binding differed among the species. Some 
species like e.g., rats, showed a higher fluorescence after incubation with HBVpreS/2-48myr-K-FITC 
than other species like e.g., humans. However, also the unspecific binding of HBVpreS/2-
48myr(D11,13)-K-FITC was enhanced. In order to normalize specific binding, the signal intensity of 
HBVpreS/2-48myr-K-FITC was divided by that of HBVpreS/2-48myr(D11,13)-K-FITC and subtracted by 1 
(if both types of binding contribute equally (factor = 1), no specific binding takes place) (see Figure 
10B). Despite relatively high error bars that probably resulted from intra-species variations, the 
overall tendency showed that hepatocytes from humans, dogs, rabbits and rats specifically bound 
HBVpreS/2-48myr-K-FITC, whereas cynomolgus monkeys, rhesus monkeys or pigs did not. 
Flow cytometry with freshly isolated woodchuck hepatocytes showed a specific binding of 
HBVpreS/2-48myr-K-FITC to these cells (C). Although being characterized by a relatively high 
background binding of HBVpreS/2-48myr(D11,13)-K-FITC (~ 12 % positive cells) binding was specific 
since it could be competed with HBVpreS/2-48myr (reduction to background levels, 13.6 % positive). 
In contrast, competition with HBVpreS/2-48myr(D11,13) had no effect (30.2 % positive). 
To exclude artifacts, each preparation was checked for cell viability by a control stain with propidium 
iodide (or Hoechst, respectively). A potential contamination with non-parenchymal cells in the 
experiment shown in (A) could be excluded since uptake of acetylated low-density lipoprotein, a 
marker for sinusoidal cells, was not observed (data not shown). The fresh woodchuck hepatocyte 
preparation contained also non-parenchymal cells, but these could be “gated out” by flow cytometry 
due to their small size. 
3.3 Characterization of preS1-receptor binding 
3.3.1. The presence of a preS1-receptor depends on the differentiation state of the cell 
Hepatocytes isolated from the liver are known to undergo a process in cell culture, referred to as de-
differentiation (review (Elaut et al. 2006b). For unknown reasons, dedifferentiation can be slowed 
down by the addition of dimethylsulfoxide (DMSO) to the cell culture medium. 
Dedifferentiation of PHH and PTH is accompanied by a loss of the susceptibility to HBV. This has been 
observed also for DHBV and the infection of primary duck hepatocytes. HepaRG cells, in contrast, 
gain susceptibility during a DMSO-induced differentiation process (Gripon et al. 2002), substantiating 
the assumption that permissiveness towards HBV depends on the differentiation state of the cell. 
To investigate, whether this restriction might reflect a differentiation-dependent expression of a 
preS1-receptor, we tested binding of HBVpreS/2-48myr-K-FITC to undifferentiated and differentiated 
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HepaRG cells. Interestingly, peptide binding could be detected only on the differentiated HepaRG 
cells (Figure 11A, left panel). No signal was detected on undifferentiated cells. This directly 
demonstrated that the presence of a functional preS1-receptor depends on the differentiation state. 
For that reason, the lacking susceptibility of the undifferentiated HepaRG cells might be explained by 
a lack of preS1 receptor expression. 
 
 
Figure 11: HBVpreS/2-48myr-K-FITC binding depends on the differentiation state of the cell. (A) HBVpreS/2-
48myr-K-FITC (200 nM) was incubated with HepaRG cells 5 days (d) (undifferentiated) and 28 d after plating, 
including a 2-weeks DMSO treatment (differentiated). PMH were incubated on d1 (differentiated) and d8 
(dedifferentiated) after isolation and cultivation without DMSO. (B) HuH7 and HepG2 cells were stained with 
HBVpreS/2-48myr-K-FITC in a confluent state (-DMSO) and after a 2-weeks DMSO treatment (+DMSO). PHH 
cultivated with or without DMSO were stained on d1 and d3 after plating (i.e. d2 and d4, respectively after 
isolation). 
Vice versa, we tested if PMH lose the ability to bind HBVpreS/2-48myr-K-FITC during dedifferentiation. 
For this, peptide binding was performed on day 1 after isolation of PMH and, after a prolonged 
period of cultivation in absence of DMSO. As shown in Figure 11A (right panel), hepatocytes from the 
same preparation were able to specifically bind HBVpreS/2-48myr-K-FITC on day 1, but lost this ability 
within 8 days of cultivation. A time-course experiment sustained this observation by measuring the 
progressive loss of binding ability within 6 days by flow cytometry (unpublished data, Stefan Mehrle). 
Consistent with the finding that HBV susceptibility of PHH can be maintained over time by the 
presence of DMSO, also the loss of the peptide binding ability could be delayed (Figure 11B). In 
contrast to cells that were cultivated without DMSO, PHH cultivated in presence of this 
differentiating agent were able to bind HBVpreS/2-48myr-K-FITC on day 7 after isolation. 
To test if hepatoma cell lines, generally regarded as undifferentiated, bind preS1-lipopoptides, we 
incubated confluent cultures of HepG2 and HuH7 cells with HBVpreS/2-48myr-K-FITC. Both hepatoma 
cell lines display typical functions of the liver but are immortalized and do not achieve cellular 
differentiation. As shown in Figure 11B HepG2 and HuH7 did not bind HBVpreS/2-48myr-K-FITC. 
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Interestingly, also a treatment with DMSO for 2 weeks did not induce a binding ability of these cells. 
This indicated that HepG2 and HuH7 lack the ability to express a functional preS1-receptor. It might 
as well provide an explanation for their non-susceptibility towards HBV infection. 
3.3.2. Glycosaminoglycans do not play a substantial role in receptor-binding of HBVpreS/2-48myr 
As for many other viruses, glycosaminoglycans have been found to mediate primary attachment of 
HBV to the cell (Schulze et al. 2007). The attachment of HBV with negatively charged side chains of 
heparan sulfate proteoglycans is preS1-dependent and can be inhibited with high concentrations of 
heparin or suramin.  
Although affinity chromatography columns containing heparin sepharose cannot bind HBVpreS/2-
48myr as a part of the preS1-sequence (Andreas Schulze, PhD thesis), the role of proteoglycans in the 
interaction of HBVpreS/2-48myr-K-FITC with hepatocytes was investigated. Therefore, binding to 
PMH was competed with heparin and suramin in concentrations that have been shown to inhibit 
HBV binding to HepaRG cells. As seen in Figure 12 neither heparin, nor suramin showed an effect on 
HBVpreS/2-48myr-K-FITC binding to the plasma membrane. This provided a first indication that 
glycosaminoglycans do not play a pivotal role in peptide binding. However, the functionality of this 
assay has not been tested. The validity of the visual read-out was provided by the fact that the effect 
of binding competition with an excess of unlabeled HBVpreS/2-48myr could be detected by a loss of 
plasma membrane-bound signal (Figure 12, right). 
 
 
Figure 12: Binding of HBVpreS/2-48myr-K-FITC could not be inhibited by heparin or suramin. PMH grown on 
cover slips were incubated with 200 nM of the peptide in presence (+ heparin/ +  suramin/ + HBVpreS/2-48myr) 
or absence (not competed) of competitor, and spinning disk confocal microscopy was performed with a 600x 
magnification on fixed cells. FITC-fluorescence is shown in green, nuclei were stained with DAPI (blue). 
3.3.3. The preS1-receptor is sensitive to protease digestion 
To get first insights into the nature of the preS1-receptor molecule, we investigated if protease 
digestion of plasma membrane surface proteins by Glu-c and trypsin has an impact on subsequent 
binding of HBVpreS/2-48myr-K-FITC. 
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As determined by flow cytometry, binding of HBVpreS/2-48myr-K-FITC could be reduced to 
approximately 40 % of the untreated control, when PMH were pre-treated with 40 µg Glu-c (see 
Figure 13). Pre-treatment with trypsin had a similar effect. The sensitivity of the preS1-receptor to 
proteolytic digestion clearly suggested a proteinaceous character of this still unknown molecule. 
Since both enzymes were removed after pre-incubation by extensive washing of the cells, one could 
argue that the reduction of binding might result from peptide digestion by residual enzymatic 
activity. A control experiment in which the reaction was stopped by enzyme saturation (addition of 
10 % FCS), excluded this possibility (data not shown). 
 
 
Figure 13: Proteolytic digestion of surface proteins reduces peptide binding in a concentration-dependent 
manner. Freshly isolated PMH were pre-treated with Glu-c (20/ 40 µg) and trypsin (0.005/ 0.015 %). After 
removal of the enzymes by extensive washing, cells were incubated with 200 nM HBVpreS/2-48myr-K-FITC, and 
cell-associated fluorescence was measured by flow cytometry. Histograms of the fluorescence intensities are 
depicted on the left; normalized mean fluorescence values (right) are given as percentages of the untreated 
control. 
 
3.4 Characterization of the pharmacodynamic behavior of HBVpreS/2-48myr and the kinetics of 
receptor binding 
Despite the very detailed knowledge about sequence requirements of HBVpreS/2-48myr-mediated 
infection inhibition, little is known about its binding mechanism and the mode of action. HBVpreS/2-
48myr does not prevent virus binding to the cell at concentrations that completely inhibit infection. It 
presumably interferes with a post-attachment step like endocytosis or fusion. The IC50 of HBVpreS/2-
48myr on HepaRG cells is described with 0.14 nM (Schulze et al. 2010).  
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Application of peptide shortly after virus inoculation has no effect, but when pre-incubated, 
HBVpreS/2-48myr-mediated infection inhibition lasts for several hours (t1/2 ≈ 12 hours, (Gripon et al. 
2005). To get insight into the mechanism of action of HBVpreS/2-48myr, the binding and kinetics of 
HBVpreS/2-48myr-K-FITC-receptor interaction were investigated. 
3.4.1. HBVpreS/2-48myr-K-FITC-receptor binding represents a bimodal binding mechanism 
Similar to radio-ligand binding studies, the binding curve of HBVpreS/2-48myr-K-FITC was calculated to 
characterize the peptide-receptor interaction. Therefore, flow cytometry was performed to measure 
the cell-associated fluorescence intensity of PMH, incubated with a serial dilution of HBVpreS/2-
48myr-K-FITC. Unspecific binding was determined by incubation with HBVpreS/2-48myr(D11,13)-K-FITC 
and HBVpreS/1-48-K-FITC. 
As expected, PMH incubated with the wild type peptide showed increasing fluorescence intensities 
with increasing concentrations (see Figure 14). However, the curve resulting from these primary data 
did not show saturation within the concentration range tested (0.05 µM - 3.2 µM). PMH that were 
incubated with HBVpreS/2-48myr(D11,13)-K-FITC showed a linear, although delayed increase of 
fluorescence, compared to HBVpreS/2-48myr-K-FITC. Concentrations below 0.4 µM did not result in 
significant binding. Since the non-myristoylated peptide did not show interaction even at the highest 
concentrations used, it was assumed that the linear increase of HBVpreS/2-48myr-K-FITC and 
HBVpreS/2-48myr(D11,13)-K-FITC resulted from an unspecific, myristoylation-dependent binding. 
The remarkable difference of the curves at low concentrations, however, indicated different binding 
mechanisms for the wild type and the mutant peptide. In order to display specific binding only, the 
fluorescence signals of HBVpreS/2-48myr-K-FITC-binding were normalized by subtraction of the signals 
of HBVpreS/2-48myr(D11,13)-K-FITC-binding. The resulting curve showed the characteristics of a 
typical receptor-ligand interaction, i.e. hyperbolic increase and saturation. This indicated the 
presence of two modes of binding, being (1), an unspecific, myristoylation-dependent binding at high 
concentrations, and (2), a highly specific, sequence-dependent binding at low concentrations. 
Consistent with that bimodal binding mechanisms have been described for other myristoylated 
proteins also (review (Resh 1999). 
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Figure 14: The bimodal binding mechanism of HBVpreS/2-48myr-K-FITC. (A) PMH were incubated with 
increasing concentrations (0.05, 0.1, 0.2, 0.4, 0.8, 1.6 and 3.2 µM) of HBVpreS/2-48myr-K-FITC (green), 
HBVpreS/2-48myr(D11,13)-K-FITC (red), and HBVpreS/1-48-K-FITC (orange). Mean fluorescence intensity was 
measured by flow cytometry and plotted against the respective peptide concentration. Data were normalized 
by subtracting the autofluorescence. The black line represents specific binding only, normalized as indicated in 
the graph. (B) Curve fitting of the data normalized for specific binding only (range 0 - 1600 nM) was performed 
using the function “non-linear regression - specific binding” (GraphPad). KD and Bmax were calculated 
automatically based on the formula described in the text. (C) Linear display of the binding data in a Scatchard 
plot. 
3.4.2. Determination of the KD and Bmax of the peptide-receptor interaction 
The normalized data obtained by subtraction of the unspecific binding (see Figure 14A) were used to 
calculate a theoretical binding curve. Based on this it was possible to calculate the dissociation 
constant KD as a measurement of the affinity of the HBVpreS/2-48
myr-K-FITC-receptor interaction.  
KD describes the affinity of an interaction as the concentration that is needed to achieve a half-
maximal binding at equilibrium. By extrapolating ligand-binding to the maximal binding 
concentration (Bmax), the half-maximal saturation directly allows the calculation of KD using the 
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function                
      
. With                             ,                 , and                  , this 
equation can be solved to     
               
    
. With   max            the expression is equal to    
       
    
.  
      here was the fluorescence intensity (a.u.), and     the peptide concentration (nM). The software 
GraphPad Prism5 was used for extrapolation and determination of Bmax and KD. A correlation 
coefficient R2 provided information about how well the theoretical curve fits the real data points.  
The theoretical curve resulting from the normalized data is shown in Figure 14B. Linear display of 
these data is shown in a Scatchard plot (Figure 14C). The slope of the linear regression determines 
the KD by the linear equation        , with         . 
Based on these calculations, the KD of the interaction between HBVpreS/2-48
myr-K-FITC and the preS1 
receptor was determined to be approximately 60 nM. 
It could be argued that the experimental set-up used here did not respect the percentage of 
unbound peptide, since only cell-associated fluorescence was measured. However, we applied 
peptide in such an excess that the reduction of unbound ligand in the supernatant could be 
neglected. Therefore, the number of remaining ligand molecules was defined as equal to the 
respective input concentration. (Example: assuming a hypothetical number of 300 000 preS1-
receptors per cell and a number of 6 x 107 peptide molecules applied per cell (= 100 nM), the 
reduction of ligand would result in a number of 5.97 x 107 molecules/cell. This reduction is negligible.) 
However, this assay was not suited to determine a concentration of Bmax, since this would have 
required the correlation of fluorescence to a defined fluorophore-peptide concentration. To calculate 
the total number of receptors on the cell surface of hepatocytes, we performed a similar experiment 
with PRH, PHH and HepaRG cells, using unlabeled HBVpreS/2-48myr. Cell-associated peptide was 
quantified by HPLC-MS/MS. The cells were incubated with concentrations ranging from 1 to 1000 
nM, and cell-associated HBVpreS/2-48myr was measured by Prolytic GmbH in ng peptide/ml. 
Determination of the cell weight enabled us to describe cell-associated peptide as ng peptide/g 
tissue. 
Since unspecific, myristoylation-dependent binding above 400 nM was observed before, the 
calculations of the theoretical binding curves respected unspecific binding as a linear component 
(      max       D                As depicted in Figure 15, PRH and PHH were characterized 
by a different Bmax for HBVpreS/2-48
myr, while the affinity of both receptors for HBVpreS/2-48myr was 
similar. This difference might reflect the previous observation that primary hepatocytes from 
different species exhibited distinct binding capacities (Figure 10). 
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Figure 15: Binding curves of the interaction of HBVpreS/2-48myr with PRH, PHH and HepaRG cells. Freshly 
isolated PRH (A), cryopreserved PHH (B), or plated HepaRG cells (C) were incubated with 1, 10, 25, 40, 100, 400 
and/ or 1000 nM HBVpreS/2-48myr. Cell-associated peptide was quantified by HPLC-MS/MS. Data were 
processed using the GraphPad Prism5 non-linear regression analysis. (C) Data obtained by incubation of 
HBVpreS/2-48myr on HepaRG cells were plotted before (left), and after (right) normalization by subtraction of 
unspecific binding. Unspecific binding was determined by measurement of HBVpreS/2-48myr(D11,13) (400 and 
1000 nM), normalized data points are indicated with red color. Bmax = maximal binding concentration (ng 
peptide/ g cells), KD = dissociation constant (nM), R
2 = correlation coefficient. 
 
Surprisingly, HepaRG cells showed a reduced binding capacity, compared to PRH or PHH. As shown in 
Figure 15C, concentrations up to 100 nM resulted in measurements that were close to the detection 
limit of the assay. Although these data did not allow calculation of a reliable binding curve, HepaRG 
cells bound at least 10-fold less peptide (approximately 50 ng/ g cells), compared to PHH 
(approximately 500 ng/ g cells). This is consistent with infection data that show generally lower 
values compared with PHH. Additionally, it has been shown that only 10 % of the HepaRG-culture is 
infected (Andreas Schulze, unpublished data).  
An approach to normalize binding was performed by an incubation with 400 and 1000 nM of 
HBVpreS/2-48myr(D11,13). Since the molecular weight of this mutant peptide is equal to that of 
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HBVpreS/2-48myr, it should be detected by HPLC-MS/MS under the same conditions. Indeed, 
unspecific binding could be measured, resulting in values of 37 ng/ g (at 400 nM) and 97 ng/ g (at 
1000 nM). 
When the binding curve of HBVpreS/2-48myr was normalized by subtraction of the unspecific binding, 
this led to a theoretical curve, giving a Bmax at very low concentrations (67 ng/ g cells). This implied a 
saturation of binding sites on HepaRG cells already at low concentrations. 
However, the binding curves presented here give only a first indication of the dimensions of KD and 
Bmax. A statistically reliable interpretation would have required much more data points. 
3.4.3. HBVpreS/2-48myr-K-FITC displays fast binding to its receptor 
In order to get insights into the kinetics of HBVpreS/2-48myr-K-FITC-receptor binding, a time-course 
experiment was performed on PHH. Plasma membrane-bound fluorescence intensity in confocal 
images was determined after incubation with HBVpreS/2-48myr-K-FITC for different time periods. As 
seen in Figure 16A, the fluorescence intensity raised with increasing incubation times. A signal could 
be detected after only 1 minute of incubation, and equilibrium of binding was reached after 
approximately 10 minutes. After that, no significant increase of fluorescence could be detected. This 
is in accordance with observations made by Gripon et al. (2005), who showed that the full inhibitory 
potential of HBVpreS/2-48myr (800 nM) is established on HepaRG cells after 15 minutes of pre-
incubation. 
3.4.4. The peptide-receptor complexes are retained on the plasma membrane with a half-life of 
approximately 11 hours 
To determine the stability of the peptide-receptor complex, PMH were incubated with HBVpreS/2-
48myr-K-FITC for a defined time period, washed and further cultivated without the peptide. Fixation at 
different time points after peptide removal and quantification of the remaining fluorescence enabled 
the determination of the half-life of HBVpreS/2-48myr-K-FITC-receptor complexes on the plasma 
membrane. 
As depicted in Figure 16B, fluorescence at the plasma membrane was still visible after 18 hours. This 
suggested retention of the peptide on the plasma membrane with a long half-life (t1/2), that was 
calculated to be approximately 11 hours. 
This correlated with the t1/2 described by (Gripon et al. 2005), who determined the time needed to 
regenerate HepaRG-susceptibility after removal of HBVpreS/2-48myr. Gripon and colleagues 
determined t1/2 to approximately 12 hours. In vivo biodistribution studies tracking iodinated 
HBVpreS/2-48myr-YI131 in mice led to a slightly higher t1/2 ≈ 16 hours (Alexa Schieck, unpublished 
results). 
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Figure 16: HBVpreS/2-48myr-K-FITC binds to its receptor in a fast and stable manner. (A) PHH were incubated 
with 200 nM HBVpreS/2-48myr-K-FITC for 1, 2, 5, 10, 20, 40 or 60 minutes. After incubation, cells were washed 
and immediately fixed. Fluorescence was documented by confocal microscopy (left, blow-ups). Grey values 
measured in the images reflected the amount of bound peptide and were plotted over time (right). (B) PMH 
were incubated for 4 hours with 200 nM HBVpreS/2-48myr-K-FITC. Peptide was removed and cells were re-
incubated for 4, 8, 16, 20 and 24 hours. Fluorescence was documented by confocal microscopy (left), grey 
values measured in the images were depicted as percentages of the maximum fluorescence observed at t = 0 h 
(right). The half-life time t1/2 was determined by the linear equation y = mx + b, with m (slope) and b (y-
intercept) as indicated and y = 0.5. 
3.5 High-resolution microscopy and sub-cellular localization of HBVpreS/2-48myr-K-FITC 
High-resolution microscopy such as spinning disk confocal or total internal reflection fluorescence 
(TIRF) microscopy was performed to localize HBVpreS/2-48myr binding sites on a sub-cellular level.  
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3.5.1. Spinning disk confocal microscopy revealed binding primarily on the cell surface 
Three-dimensional image reconstruction revealed an almost exclusive binding of HBVpreS/2-48myr-K-
FITC to the plasma membrane of PMH (Figure 17). Therefore, Z-stacks of fixed cells were processed 
by deconvolution and back-projected to a three-dimensional picture. The ortho-sliced view shows a 
representative cell from the side. 
 
 
Figure 17: HBVpreS/2-48myr-K-FITC binds to the plasma membrane and is organized in clusters. (A) Spinning 
disk confocal microscopy was performed with fixed PRH that were incubated with 200 nM HBVpreS/2-48myr-K-
FITC for 1 hour. Z-stacks were taken with a 1000x magnification and a Z-spacing of 150 nm. Stacks were 
reconstructed from non-deconvolved (left) or deconvolved (right) images. Upper panels represent maximum 
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intensity projections, lower panels the corresponding side views. (B) 3-D animation of a reconstructed, 
deconvolved Z-stack is provided in the supplementary material. (C)  Clusters of fluorescence could be observed 
on the bottom side (1) and on the top of the cells (2, see arrows). Green: HBVpreS/2-48myr-K-FITC, blue: nuclei 
stained with DAPI. 
Since deconvolution of images is prone to create artifacts, an example of a non-deconvolved versus a 
deconvolved image is presented to demonstrate that the overall appearance of peptide did not 
change, while the clarity of the image improved. 
Although described differently by (Glebe et al. 2005), who showed uptake of HBVpreS/2-48myr to PTH 
and HepG2 cells, we could not confirm an intracellular localization of HBVpreS/2-48myr-K-FITC. 
However, future experiments should include a control of the endocytic activity of the cells. 
The plasma membrane-bound fluorescence was found to be organized in clusters. As seen in Figure 
17B and C, and the corresponding movie (see supplementary material), these clusters were present 
on both, the upper, medium-directed cell surface, and the bottom side. 
3.5.2. Total internal reflection fluorescence microscopy: analysis of live cells showed the presence 
of finger-like plasma membrane protrusions that bound HBVpreS/2-48myr-C-Atto565 
Total internal reflection (TIRF) microscopy was performed as an alternative high-resolution 
microscopy technique. This required the use of a peptide labeled with the more photostable 
fluorophore Atto565.  
Live PMH were therefore incubated with HBVpreS/2-48myr-C-Atto565 and HBVpreS/2-48myr(D11,13)-
C-Atto565, and fluorescence was monitored using the TIRF modus. Shown in Figure 18A is the 
fluorescence of HBVpreS/2-48myr-C-Atto565 bound to a cell. Similar to the clusters observed by 
spinning disk confocal microscopy, also TIRF microscopy revealed the presence of fluorescence that 
was organized in clusters that appeared more dotted. The control peptide HBVpreS/2-48myr(D11,13)-
C-Atto565 did not bind to hepatocytes (data not shown). 
Additionally to the clustered binding phenotype, we detected fluorescent finger-like protrusions of 
the plasma membrane. Time-lapse acquisitions of live cells revealed that these protrusions showed 
movement (see movie). That these structures were present also on fixed cells can be seen in the 
confocal image shown in Figure 18A (right). 
To get an impression of the kinetics of HBVpreS/2-48myr-C-Atto565 binding in real time, hepatocytes 
were imaged immediately after addition of the peptide. As depicted in Figure 18B, we detected 
association and dissociation of fluorescent structures throughout the whole time lapse (20 seconds). 
To display and characterize only a fraction of these fluorescent structures, an axis was defined in x,y 
and the fluorescence along this axis was displayed by creation of a kymograph. Thereby, mainly two 
different binding forms were detected: one being characterized by a stability in x,y-position not 
showing dissociation, the other by changes of the x,y-position and only transient binding. Changes of 
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the x,y-position reflect a lateral movement. The majority of binding events, however, was 
represented by a stable interaction without dissociation or lateral mobility. 
 
 
Figure 18: Binding of HBVpreS/2-48myr-C-Atto565 observed by TIRF microscopy in real-time. (A) PMH were 
incubated with 200 nM HBVpreS/2-48myr-C-Atto565 for 30 minutes, washed and live-cell microscopy was 
performed in the TIRF modus. Finger-like protrusions seen in the representative frame of a time-lapse 
acquisition (left) showed movement, as demonstrated in the supplementary movie, and were detectable also 
on fixed cells by confocal microscopy (right). (B) The interaction of HBVpreS/2-48myr-C-Atto565 with the plasma 
membrane immediately after addition of the peptide was monitored for 20 seconds. A single frame of a 
representative movie is shown in (i). Fluorescence along a randomly defined line (ii) was displayed as a function 
of time in a kymograph (iv). Two different binding types were observed, (1) and (2), that differed in their 
temporal and positional stability. 
3.5.3. A restricted lateral mobility of peptide-receptor complexes indicated an interaction with the 
cytoskeleton 
The temporal and spatial stability of some peptide-bound structures observed by TIRF microscopy 
initiated its further investigation by measuring the fluorescence recovery after photo-bleaching 
(FRAP). Using a high-powered focused laser beam, a small area within the focal plane of the PMH 
plasma membrane was photo-bleached, and the diffusion of surrounding unbleached molecules was 
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measured as a function of time. To prevent a possible replenishment with unbleached molecules 
from the medium, the peptide solution was removed from the cells before starting the acquisition. 
As a control for fluorescence recovery, PMH were stained with the amphiphilic lipid dye octadecyl 
indocarbocyanine (DiI), representing the diffusion characteristics of lipids. 
 
 
Figure 19: The peptide-receptor complexes show a restricted lateral mobility. Live PMH were incubated with 
(A) HBVpreS/2-48myr-C-Atto565 (200 nM) for 1 hour or (B) DiI (5 µl/ ml) for 30 minutes. Cells were washed and 
time lapses were acquired for 34 seconds. Bleaching was performed after 4 seconds. Fluoresence was 
quantified in the bleached region (solid lines) and a non-bleached control region (dotted lines). Blow-ups from 
representative frames of the experiment shown in (A) are depicted in (C). 
 
As seen in Figure 19, bleaching of HBVpreS/2-48myr-C-Atto565 led to a loss of fluorescence that was 
not restored within the measured time period (30 seconds). In contrast, the DiI control stain showed 
rapid recovery of fluorescence within approximately 6 seconds. The fluorescence intensity of the 
bleached area and a non-bleached control region was plotted as a function of time to quantify 
recovery of fluorescence (A and B). Images depicted in (C) represent single frames from a 
representative time lapse experiment, showing the area of interest on HBVpreS/2-48myr-C-Atto565-
incubated hepatocytes before and 0, 10, 20 and 30 seconds after the bleaching event. 
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These data indicated a restricted lateral mobility of the peptide-receptor complexes which was 
consistent with our previous observation of a temporal and spatial stability in TIRF microscopy. The 
rapid diffusion of DiI within the plasma membrane demonstrated the functionality of this assay. 
3.5.4. Clusters of fluorescence showed a partial co-localization with actin 
Restricted lateral mobility is assumed to be mediated by an interaction with the cytoskeleton. To get 
an impression whether this interaction can be visualized directly, co-localization studies were 
performed with HBVpreS/2-48myr-K-FITC and phalloidin-Alexa565. Phalloidin, a toxin made by the 
mushroom Amanita phalloides, binds F-actin with a high-affinity. 
Interestingly, when PMH were incubated with HBVpreS/2-48myr-K-FITC, fixed and subsequently 
stained with phalloidin-Alexa565, we regularly detected an association of peptide and actin in the 
clustered structures that had been observed previously by confocal microscopy (Figure 17). These 
structures were present on the plasma-directed and the bottom membrane. Striking was the 
appearance of spots of actin that were surrounded by ring-like structures of bound peptide (B, 
arrows).  
A block of actin polymerization by treatment of the cells with cytochalasin D prior to peptide binding 
resulted in a rearrangement of the actin cytoskeleton, but in no severe alteration of the peptide 
binding. We had the impression that the outer membrane borders and finger-like protrusions 
showed a reduced peptide binding, but the overall distribution was not changed obviously. However, 
actin foci remained accociated with peptide also after cytochalasin D treatment. 
Most of the endocytotic pathways that are used by viruses to enter a cell (clathrin- or caveolin-
mediated endocytosis, or macropinocytosis) typically involve the presence of actin.  The association 
of actin with the preS1-receptor complexes suggests an involvement of actin during HBV entry. 
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Figure 20: HBVpreS/2-48myr-K-FITC colocalizes with actin. (A) PMH that were untreated (upper panel) or pre-
treated with 40 µM cytochalasin D (lower panel) were incubated with 200 nM HBVpreS/2-48myr-K-FITC (green). 
After PFA-fixation, actin was stained with phalloidin-Alexa565 (red) and confocal microscopy was performed 
with a 1000x magnification. Nuclei were stained with DAPI (blue). (B) Depicted is a blow-up of a reconstructed 
Z-stack from cells incubated with HBVpreS/2-48myr-K-FITC and stained with phalloidin-Alexa565. Co-localization 
of actin and peptide was observed on the cell bottom (upper left) and the corresponding side-views. Actin 
spots surrounded by peptide are indicated by arrows. (C) Animated reconstruction of the example shown in B, 
see movie in the supplementary material. 
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3.6 Production, characterization and visualization of fluorescently labeled HBV 
In order to compare the kinetic behavior of HBVpreS/2-48myr-K-FITC with that of virions, it would be 
beneficial to directly track HBV particles in real time. Fluorescent labeling has been described for 
many viruses (e.g. HIV-1, SV40), but not for HBV. Its small size and the compact genome organization 
complicate the incorporation of fluorescent proteins or dyes. 
3.6.1. Production of fluorescently labeled HBV particles 
Several approaches were followed to fluorescently label HBV particles: Besides the incorporation of 
amphiphilic probes such as octadecyl indocarbocyanines (DiI) or octadecyl oxacarbocyanines (DiO) or 
lipid analoga like 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-carboxyfluorescein (PE-FITC), we 
applied a chemical labeling strategy based on the reaction of succinimidyl esters (Alexa488 
succinimidyl ester) with primary amines on HBV envelope proteins. 
The labeling with DiI or DiO resulted in the formation of aggregates during purification and was not 
further followed. The incorporation of the phospholipid derivate PE-FITC into the HBV envelope 
membrane resulted in fluorescently labeled HBV particles that could be characterized on a single-
particle level. However, infectivity of HBV-PE-FITC particles could not be demonstrated. Moreover, 
FITC-labeled particles were not suited for live-cell experiments due to the photo-sensitivity of FITC. 
Particle labeling with Alexa488 succinimidyl esters yielded fluorescently labeled particles that could 
be characterized on a single-particle level, that were infectious, and well detectable on HepaRG cells. 
Therefore, highly purified HBV from HepAD38 cell culture supernatant was labeled with Alexa488 
succinimidyl ester. The latter reacts with primary amines as present in lysines in the HBV envelope 
proteins under formation of stable amide bonds. 
After labeling, unbound dye was removed by heparin-affinity chromatography, and the viral peak 
fractions were further purified and concentrated by sucrose-density gradient centrifugation. As a first 
control the sucrose gradient was checked after centrifugation for the presence of fluorescent band(s) 
(not shown). 
3.6.2. Biochemical characterization of HBV-Alexa488 
Fractions from the sucrose-density gradient centrifugation were analyzed for their HBV DNA content 
by DNA dot-blot and the presence of Alexa488-fluorescence by fluorometry (Figure 21A). Viral 
proteins were detected by Western blotting (B) and the purity of the preparation was checked by 
silver gel analysis (C). 
As demonstrated by a representative HBV-Alexa488 preparation, HBV-DNA could be detected in 
fractions 7 to 10, with a DNA-peak in fraction 9. Excitation with 488-nm light resulted in an emission 
Results  56 
of 520-nm fluorescence in the fractions 6 to 12. A possible explanation for the drop of fluorescence 
in fraction 9 (HBV-DNA peak) could be e.g. quenching of fluorescence. This would implicate an over-
labeling of particles. Fluorescence in the fractions 11 and 12 that did not contain HBV-DNA might 
result from co-purification and labeling of L-containing filaments. The high fluorescence in the earlier 
fractions 6 and 7 could not be explained but might be derived from protein-contamination. 
 
 
 
Figure 21: Biochemical analysis of fractions from a sucrose-density gradient. (A) HBV-DNA was measured in 
fractions from a sucrose-density gradient by DNA dot blot (left y-axis, black curve). Alexa488-fluorescence was 
measured with a fluorometer (right y-axis, green curve). Fractions 4 to 15 were analyzed. (B) SDS-PAGE and 
subsequent Western blotting detected HBV-L protein (39/42 kDa) by the preS1-specific monoclonal antibody 
Ma18/7 (upper part of the blot) and core protein (22 kDa) by the polyclonal rabbit serum H363 (lower blot) on 
the same blot. Sizes of the protein marker are indicated left. (C) Protein content in the fractions was visualized 
by silver staining of the proteingel after SDS-PAGE. Asterisks indicate L-protein or core-protein, respectively. A 
size marker is included in the left lane. (A), (B) and (C): each analysis was performed with a 5 µl sample of the 
respective fraction. 
 
Results  57 
A Western blot detected L-protein with the monoclonal antibody Ma18/7 in the fractions 7 to 12, 
with a peak in fractions 9, 10 and 11. Since fraction 12 did not contain HBV-DNA or core-protein 
detectable by Western blot with H363, it is likely to contain co-purified HBV filaments. However, a 
silver gel providing information about the overall protein content showed the presence of a ~ 20 kDa 
protein in fraction 12, indicating the presence of core protein. This discrepancy could be explained by 
the co-purification of empty, enveloped cores, but was not further investigated.  
For further analysis samples were taken from fraction 8 or 9. 
3.6.3. Microscopic characterization of HBV-Alexa488 showed the presence of single particles and 
aggregates 
To characterize the sucrose-density gradient peak fraction by fluorescence microscopy, 10-µl samples 
from fraction 8 and fraction 4 were mounted on glass slides and analyzed by spinning disk confocal 
microscopy. As seen in Figure 22A, the sample derived from a virus peak fraction showed the 
presence of fluorescent particles, whereas a control sample from fraction 4 did not. HBV-Alexa488 
particles could be detected with an exposition time of 300 ms. 
To analyze the fluorescence of single particles, fluorescence intensities were measured by an ImageJ 
function and plotted as a profile. As seen in Figure 22B (upper panel) single particles showed a 
Gaussian distribution of the fluorescence intensity. Although the size of the fluorescent spot (Ø ~ 200 
nm) does not directly reflect the size of its origin, it was defined as characteristic for single particles. 
In contrast to a single particle, aggregates were represented by a broader distribution of the 
fluorescence (Figure 22B, lower panel). The fluorescence intensity profile of the aggregate shown 
here as an example, was additionally characterized by two peaks. This could be due to the presence 
of two (main) sources of fluorescence in close proximity. Therefore, the fluorescence intensity 
profiles showed overlapping curves that could not be resolved due to the optical limitations. 
A statistical analysis of particle sizes within a preparation is shown in (C). Measurement of particle 
sizes by the ImageJ function particle analysis showed, that most particles possessed a small size of 
one or a few pixel2 (1 pixel2 ~ 8.1 nm2). However, the preparation contained also a low number of 
aggregates (up to 87 pixel2). 
Taken together, these data demonstrated that fluorescently labeled, single HBV-Alexa488 particles 
could be detected with an exposition time of 300 ms. 
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Figure 22: Microscopic analysis of HBV-Alexa488 particles. (A) 10-µl samples of a peak fraction (fraction 8) and 
a side fraction (fraction 4) were mounted on glass slides and monitored  with the 488-nm laser line by spinning 
disk confocal microscopy with a 1000x magnification. (B) The profiles of the fluorescence intensities of a 
representative single particle (upper panel) and an aggregate (lower panel) were measured using the ImageJ 
plug-in “plot profile”. Fluorescence (grey value) is shown as a.u. and the distance is given in µm. (C) The 
distribution of particle sizes within 3 representative pictures of the fraction 8 was determined by the ImageJ 
plug-in “particle analysis”. Particle sizes are given as (pixel2), numbers of particles (counts) are indicated on the 
y-axis. 
3.6.4. HBV-Alexa488 is highly infectious on HepaRG cells 
To test whether HBV-Alexa488 is infectious, HepaRG cells were inoculated with samples from the 
peak fraction (8) and a side fraction (3) as negative control. HBeAg and HBsAg as markers for 
infection were measured in the supernatant collected from day 4 to 7, or day 7 to 11 post infection. 
As demonstrated in Figure 23 an infection was established using Alexa488-labeled HBV. As a positive 
control we used PEG-precipitated stock virus. The HBsAg-measurement revealed an approximately 6-
fold higher HBsAg value for HBV-Alexa488 compared with the PEG-virus. This might be explained by a 
6.25-fold higher MGE/ cell in case of HBV-Alexa488. A quantitative measurement of the multiplicity 
of infection, however, would need the comparison with an equally produced, non-labeled HBV. 
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Figure 23: Infectivity of HBV-Alexa488. Differentiated HepaRG cells were inoculated o/n without (not infected) 
or with PEG-precipitated stock virus (~ 1 x 104 GE/ cell), or HBV-Alexa488 (~ 6.25 x 104 GE/ cell) from fraction 8 
(peak fraction), or a corresponding volume of fraction 3 (side fraction) from the sucrose-density gradient 
shown in Fig. 21. Markers for infection were measured by ELISA: HBsAg was measured in the supernatant 
collected from day 4 to 7 (A) and HBeAg was determined from day 4 to 7 and 7 to 11 (B). Cut-off of the assays 
was HBsAg: 0.05 IU/ ml, HBeAg: 1 RLU. 
3.6.5. HBV-Alexa488 binding to differentiated HepaRG cells can be enhanced by PEG and inhibited 
by heparin 
In order to check HBV-Alexa488-binding to cells, differentiated HepaRG cells were inoculated with 
the fluorescently labeled virus for 1.5 hours, washed and the fixed cells were analyzed by spinning 
disk confocal microscopy. As seen in Figure 24, some HBV-Alexa488 particles could be found on 
HepaRG cells when incubated in absence of polyethyleneglycol (PEG). Consistent with what has been 
described for unlabeled HBV (Gripon et al. 1993) the addition of PEG during inoculation enhanced 
particle binding significantly. A control inoculum (fraction 3) also incubated in presence of PEG did 
not show particulate fluorescence. Furthermore, binding of HBV-Alexa488 could be inhibited with 
heparin in concentrations that block HBV binding (Schulze et al. 2007), being an indication for the 
authenticity of the system. However, the specificity of this binding has to be approved in future 
experiments, e.g. by the use of neutralizing antibodies. 
The maximum intensity projection of HepaRG cells inoculated with HBV-Alexa488 that was derived 
from a different preparation provides information about the binding distribution. Although not 
quantified or validated by the use of differentiation-markers, binding appeared to be distributed over 
all cells and did not show a preference for differentiated hepatocyte-like cells. This has to be further 
tested in future. 
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3-dimensional reconstruction of Z-stacks showed a predominant localization of HBV-Alexa488 
particles on the medium-directed plasma membrane. Figure 24C and D show an ortho-sliced view 
and a representative movie included in the supplementary material. Despite the relatively long 
incubation period of 1.5 hours at 37°C, a significant uptake of these particles was not observed. 
 
 
Figure 24: HBV-Alexa488 binding to differentiated HepaRG cells. (A) HepaRG cells were incubated with HBV-
Alexa488 (fraction 8) in the presence of absence of PEG (4 %) and heparin (600 µg/ ml) for 1.5 hours at 37°C. As 
a control, cells were incubated with an inoculum from fraction 3 in presence of PEG. Pictures of fixed cells were 
taken with a 1000x magnification using spinning-disk confocal microsopy. The actin cytoskeleton was stained 
with phalloidin-Alexa546, nuclei were stained with DAPI. (B) HBV-Alexa488 from a different preparation was 
incubated with HepaRG cells as described in (A), in presence of 4 % PEG. Pictures shown in (A) and (B) 
represent maximum projections of Z-stacks. An orthogonal view (C) and an animated 3-D reconstruction (D, see 
movie in the supplementary material) of a Z-stack from the experiment shown under A, upper right. 
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4. Discussion 
 
HBVpreS/2-48myr inhibits HBV infection in vitro and in vivo with a remarkably high efficiency and 
specificity (Gripon et al. 2005; Petersen et al. 2008). Both, the integrity of the preS1-sequence in the 
essential region (amino acids 9 - 15, genotype D) and the N-terminal myristoylation of HBVpreS/2-
48myr are essential for the peptide’s inhibitory activity. Single amino acids (positions 11, 12 and 13, 
genotype D) could be identified that are crucial for infection inhibition (Engelke et al. 2006), and the 
removal of the acylation leads to an extremely reduced inhibitory potential (Gripon et al. 2005). 
Both findings tightly correlate with determinants of HBV infectivity: recombinant HBV particles, 
carrying the same point mutations in context of the L-protein, are non-infectious (Engelke et al. 
2006), and the myristoylation of the preS1-domain is absolutely essential for hepadnaviral infectivity 
(Gripon et al. 1995). This analogy strongly suggests that the virus and the preS1-peptide address a 
common factor on the hepatocyte at least at one step during infection. 
In order to characterize the interaction with this factor, the present work aimed to visualize and 
characterize receptor binding of fluorescently labeled HBVpreS/2-48myr peptides. 
4.1 HBVpreS/2-48myr binds to a receptor on the plasma membrane of HBV-susceptible 
hepatocytes in a highly sequence- and myristoylation-dependent manner 
As it has been described initially, fluorescently labeled HBVpreS/2-48myr interacts with the cell surface 
of PHH (Gripon et al. 2005). We here provide a detailed analysis of this interaction, using HBVpreS/2-
48myr-K-FITC and two control peptides, the mutant HBVpreS/2-48myr(D11,13)-K-FITC and the non-
myristoylated variant HBVpreS/1-48-K-FITC. Both controls do not inhibit the infection with HBV and 
HDV, respectively. 
Fluorescence micrososcopy and flow cytometry showed that HBVpreS/2-48myr-K-FITC specifically 
bound to the plasma membrane of HBV-susceptible cells like PHH, PTH and HepaRG cells. In contrast, 
the control peptides did not show binding, demonstrating that the interaction strictly depends on the 
integrity of the amino acid sequence and the presence of the N-terminal myristoylation. This 
completely correlated with the inhibitory potential of these peptides and directly showed that the 
lacking inhibitory activity of the control peptides is a consequence of their inability to bind to a 
specific preS1-receptor. 
The high specificity of binding could be validated by competition experiments. Whereas an excess of 
unlabeled HBVpreS/2-48myr could prevent binding of HBVpreS/2-48myr-K-FITC, even a 100-fold excess 
of the unlabeled mutant peptide had no effect. 
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4.2 The expression of an HBVpreS/2-48myr-receptor is not restricted to HBV-susceptible cells 
In vivo biodistribution studies have shown that iodinated HBVpreS/2-48myr-YI131 accumulated in the 
liver of mice, although they are not susceptible to HBV infection (Alexa Schieck, diploma thesis, see 
Figure 3). In tight correlation with the requirements for the infectivity of an HBV particle, and for the 
inhibitory activity of preS1-lipopeptides, a mutant and a non-myristoylated peptide did not exhibit a 
tropism for the liver. Instead, HBVpreS/2-48myr(D11,13)-YI131 was found to be equally distributed over 
all organs, and HBVpreS/1-48-YI131 was renally eliminated within one hour. The high specificity with 
which the wild type peptide was retained in the liver therefore indicated a hepatic presence of a 
specific preS1-receptor in these non-permissive animals. 
This finding is in complete accordance with the in vitro data described here. Our observation that 
hepatocytes from some non-susceptible species, e.g. mice (PMH) and rats (PRH), were able to bind 
HBVpreS/2-48myr-K-FITC in a highly specific manner (see Figure 9) strongly suggested an expression of 
a preS1-receptor on these cells. The restriction of PMH and PRH towards HBV infection therefore is 
not due to the lack of a preS1-receptor. Since assembly and secretion of infectious virions in PMH 
and PRH is not hampered after expression of pre- and sub-genomic HBV-RNAs (Yamamura et al. 
1990; Araki et al. 1991; Diot et al. 1992), the lacking permissiveness of these cells must be related to 
another factor. This could be for instance the absence of a co-factor during viral entry and/ or a 
restricted post-entry step. 
Further support that the expression of a functional preS1-receptor is not limited to human primates 
is provided by the finding that primary hepatocytes from Tupaia belangerii, a member of the order 
Scandentia, can be infected with HBV (Yan et al. 1996b), and that the infection can be inhibited by 
preS1-lipopeptides (Glebe et al. 2005). Our observation that PTH specifically bound HBVpreS/2-48myr-
K-FITC provided direct evidence for the presence of a functional preS1-receptor on these cells. 
Interestingly, we found - additionally to mice, rats and tupaias - a specific interaction of HBVpreS/2-
48myr-K-FITC also to hepatocytes from rabbits, dogs and woodchucks (Figure 10).  The fact that these 
species are phylogenetically only distantly related to humans implies that the preS1-receptor might 
be an evolutionary conserved molecule. 
However, the preS1-receptor is not expressed in all species, since we did not find an interaction of 
HBVpreS/2-48myr-K-FITC with primary hepatocytes from pigs, rhesus and cynomolgus monkeys. These 
in vitro data were affirmed by an in vivo analysis of the tropism of HBVpreS/2-48myr-YI131, which 
accumulated only in the liver of dogs but not cynomolgus monkeys (Alexa Schieck, unpublished data). 
This was surprising, since rhesus monkeys (Macaca mulatta) and cynomolgus monkeys (Macaca 
fascicularis) are phylogenetically much closer to humans than some of the binding-competent 
species, like e.g. dogs (order Carnivora; see Figure 25).  
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All apes (members of the superfamily Hominoidea: gibbons, orang-utan, gorilla, chimpanzees and 
humans) harbour HBV endemically and some are permissive to an experimental HBV and HDV 
infection (Barker et al. 1975). Since both, rhesus and cynomolgus monkeys, belong to a different 
superfamily (Cercopithecoidea) within the same parvorder (Catarrhini, Old World monkeys), it might 
be possible that the respective receptor homologue of a common ancestor lost the preS1-binding 
competence by mutation during the evolution of their lineage. Of course, it must remain speculative, 
if such a mutation led to the resistance against (and the extinction of) an HBV variant that had been 
endemic in this superfamily before. 
 
 
Figure 25: Phylogenetic tree of HBVpreS/2-48myr-K-FITC binding and non-binding species. The phylogenetic 
relationship between species that bind (green) or do not bind (red) HBVpreS/2-48myr-K-FITC is shown in a 
dendrogram. Distances do not reflect relative relationship. The data for each lineage were collected from: 
www.ncbi.nlm.nih.gov/taxonomy. 
 
Furthermore, our data showed that primary woodchuck hepatocytes (PWH) specifically bound 
HBVpreS/2-48myr-K-FITC, indicating the presence of a human preS1-receptor homologue on these 
cells. Although in vitro an infection of these cells with HBV failed, it could be shown that HDV, bearing 
a human (hHDV) or woodchuck (wHDV) envelope, was able to infect PWH (Caroline Gähler, 
unpublished results). The infection with hHDV was inefficient (compared to that with wHDV), but 
specific as it could be inhibited by HBVpreS/2-48myr. An addition of peptide to the wHDV infection 
had no effect. Interestingly, primary hepatocytes from rabbits showed a very similar susceptibility 
upon infection with hHDV, wHDV or HBV. They could be infected with hHDV and wHDV, but not with 
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HBV, and only hHDV infection was inhibitable with HBVpreS/2-48myr. Taken together, this indicated a 
difference in HDV- and WHV-entry that could be based on the use of different receptor molecules. 
An alternative explanation would assume that HBVpreS/2-48myr acts on the virus, by e.g. inhibiting 
fusion of viral and cellular membrane as it is described for HIV and the fusion inhibitor T-20. In this 
model both (HDV and WHV) would utilize the same receptor, but the peptide could act due to 
sequence-specificities only on the human virus. 
Our data furthermore indicated that HBV might bind (or even enter) preS1-binding-competent but 
non-susceptible hepatocytes, and that further steps in infection are restricted (e.g. membrane 
fusion, release or transport of nucleocapsids, repair of rcDNA, formation of cccDNA, etc.). HDV in 
contrast might be well able to establish a first-round, but dead-ended infection in these species. 
These possibilities have to be systematically tested in the future and may have important 
implications for the development of a small animal model for HBV and HDV. 
4.3 The presence of a proteinaceous HBVpreS/2-48myr receptor on the plasma membrane 
depends on the differentiation status of the cell 
Besides the restricted host range, a second remarkable characteristic of HBV is the limitation to 
exclusively infect differentiated hepatocytes (Gripon et al. 2002). HepaRG cells, the only permanent 
cell-culture system known to support the complete viral life cycle, need a differentiation period of 
two weeks to achieve an HBV-susceptible state. The differentiation is induced by the addition of 
DMSO, a well-known differentiating agent. Vice versa, PHH lose their susceptibility to infection within 
several days after isolation, but the permissive state can be maintained by addition of DMSO (Gripon 
et al. 1988). 
The binding experiments with HBVpreS/2-48myr-K-FITC demonstrated, that the differentiation status 
of a cell is directly reflected by the presence of a preS1-receptor. HepaRG cells in the 
undifferentiated state did not show an interaction with HBVpreS/2-48myr-K-FITC, whereas binding 
could be well detected in a susceptible, differentiated state. On the other hand, PHH lost their ability 
to bind HBVpreS/2-48myr-K-FITC during a de-differentiation process, within one week after plating. 
The loss of the binding capability could be prevented by the addition of DMSO to the culture 
medium. The same phenomenon was observed for PMH. These data provide strong evidence that 
the preS1-receptor expression depends on the differentiation state of the target cells and constitutes 
the main and maybe only restriction factor for infection in the human hepatocytes investigated here, 
that otherwise support the full replication cycle. 
Human hepatoma cell lines isolated and established from hepatocellular carcinoma, are widely used 
model systems to study liver metabolism and cytotoxicity. However, their use is less popular 
compared to that of PHH since they are considered to be less differentiated, although some of the 
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cell lines like HepG2 or Huh7 partially display differentiated liver specific functions (Knowles et al. 
1980).  
HepG2 cells have been discussed extensively as a potential infection system for HBV and support 
HBV particle production after transfection of HBV-expression plasmids. Several studies reported 
specific binding and uptake of HBV in these cells (Bchini et al. 1990; Paran et al. 2001), but credible 
evidence for a productive infection until now is missing. So far, the refractoriness of HepG2 cells 
towards HBV infection has been explained e.g. by a block in nuclear transport (Qiao et al. 1994) or 
the over-expression of a serine protease inhibitor (Lu & Block 2004). Since we neither detected 
binding of HBVpreS/2-48myr-K-FITC to HepG2 cells in an actively dividing state, nor after a two-week 
treatment with DMSO (Figure 11), we suggest that the lack of a functional preS1-receptor is the main 
reason that limits the successful HBV entry into these cells. A second well-characterized heptoma cell 
line, HuH7, that has been described to bind HBV (Qiao et al. 1994) but not to promote infection, as 
well did show an interaction with HBVpreS/2-48myr-K-FITC in neither the untreated, nor the DMSO-
treated state. Taken together, these findings further substantiate our hypothesis that the expression 
of a functional preS1-receptor is dependent on the differentiation status of a cell and represents the 
major restriction factor for infection. Hepatoma cell lines like HepG2 and HuH7 apparently lost the 
ability to express a functional preS1-receptor, maybe as a consequence of the cancerous 
transformation process. A unique feature of the hepatoma cell line HepaRG is that these cells can re-
develop a hepatocyte-like phenotype after a prolonged quiescence and maintenance at confluence in 
combination with DMSO treatment. Since HepaRG cells are less profoundly altered regarding the 
chromosomal re-arrangement (compared to the other mentioned hepatic cell lines), they have 
retained an intrinsic ability for a regulated expression of the specific preS1-receptor. 
 
Heparan sulfate proteoglycans have been described to interact with the preS1-region of the HBV L-
protein in the viral context (Schulze et al. 2007) and act as primary attachment receptors. HepG2 and 
Huh7 cells did not bind HBVpreS/2-48myr despite the presence of GAGs on their surface. Furthermore, 
competition experiments with heparin and suramin on PMH did not lead to a significant reduction of 
peptide binding. Therefore, a major contribution of GAGs to HBVpreS/2-48myr-K-FITC binding to the 
cell surface could be excluded. 
In contrast to that, peptide binding could be strongly reduced by proteolytic digestion of cell surface 
proteins (Figure 13). Even if the binding of the preS1-peptide could not be completely abolished after 
treatment of PMH with trypsin or Glu-c, the decrease of the binding capacity to approximately 40 % 
provided a direct evidence that at least one essential factor involved in the preS1-receptor 
interaction is a protein. 
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4.4 Analysis of the affinity of HBVpreS/2-48myr to its receptor 
The vast amount of viruses uses proteins on the cell surface as receptors. For HBV, only 
glycosaminoglycans (GAGs) have been described as primary attachment factors, but this family of 
macromolecules is ubiquitously distributed in the host organism. The nature of molecule(s) that 
act(s) as liver-specific receptor(s) is not characterized yet. However, the observation that binding of 
the preS1-lipopeptide to PMH can be reduced after protease-treatment of the target cells strongly 
suggested the involvement of a protein-protein interaction during receptor recognition. 
In this case, binding of HBVpreS/2-48myr to the plasma membrane should exhibit hallmarks of a 
typical receptor-ligand interaction between two protein partners, i.e. high affinity (low dissociation 
constant KD) and saturation at low ligand concentrations. 
To determine these parameters, we investigated the pharmacodynamics of HBVpreS/2-48myr-K-FITC. 
In a first approach a flow cytometry-based binding assay with PMH was established to plot a binding 
curve for the interaction with the preS1-receptor. 
As seen in Figure 14, the wild type and the two control peptides showed binding curves that were 
very different from each other. At concentrations below 400 nM, binding was detected only for 
HBVpreS/2-48myr-K-FITC. In contrast, concentrations above 400 nM lead to a parallel linear increase 
of cell-associated fluorescence for both acylated peptides, HBVpreS/2-48myr-K-FITC and HBVpreS/2-
48myr(D11,13)-K-FITC. Since the non-myristoylated peptide did not show significant binding at any 
concentration tested, it was proposed that the non-saturable binding at concentrations exceeding 
400 nM was mediated by the acyl moiety. 
In order to display specific binding only, the data of HBVpreS/2-48myr-K-FITC binding were normalized 
by subtracting the unspecific binding represented by the mutant peptide. The resulting curve was 
characterized by a hyperbolic increase to a plateau. The KD could be determined to approximately 60 
nM and ~ 90 % saturation was reached at a concentration of ~ 300 nM. Scatchard analysis of these 
data showed a linear regression, which excluded a cooperative effect during formation of the 
peptide-receptor complex. 
The total binding of HBVpreS/2-48myr-K-FITC hence involved two components: (i) a sequence- and 
myristoylation-dependent binding to a high-affinity receptor conferring liver specificity, and (ii), a 
non-saturable, low affinity interaction with highly abundant molecules (e.g. phospholipids in the lipid 
bilayer) that depends exclusively on the presence of the acyl residue. 
In an alternative approach we determined the binding dynamics of HBVpreS/2-48myr to PRH, PHH and 
HepaRG cells on the basis of quantitative mass-spectrometry analysis. Therefore, cells were 
incubated with different concentrations of HBVpreS/2-48myr, and the bound fraction was determined 
by HPLC-MS/MS (performed by Prolytic GmbH). The calculation of binding curves for the respective 
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cells allowed us to estimate the binding capacity Bmax as a relative measure for the receptor density 
on the cell surface. 
Striking differences were found in the binding capacities of these cell types. PRH exhibited the 
highest Bmax of approximately 1900 ng peptide/ g cells, and PHH showed a moderate binding capacity 
of ~ 430 ng peptide/ g cells. Although the limited number of data point restricts the statistical validity 
of this assay, these findings reflected previous results obtained by the flow cytometric analysis of 
primary hepatocytes from different species. As depicted in Figure 15, PRH showed an about 4-fold 
difference in the cell-associated fluorescence intensity when compared to PHH that were incubated 
with an equal concentration of HBVpreS/2-48myr-K-FITC. Additionally, the same phenomenon was 
observed - although not quantified - by fluorescence microscopy. Together, these experiments 
provided a direct evidence for inter-species variations in the preS1-receptor density between PRH 
and PHH. 
Compared to these two cell types, only a very low amount of bound HBVpreS/2-48myr-molecules was 
found on HepaRG cells. All peptide concentrations applied within the range of specific binding (below 
400 nM) resulted in signals that were close to the detection limit of the system. Even higher 
concentrations did not yield reliable data that could be used to plot a binding curve. It therefore had 
to be assumed that the Bmax of HepaRG cells is significantly lower than that of the primary 
hepatocytes. These findings might have important consequences for the determination of an 
effective dose of HBVpreS/2-48myr as entry inhibitor, and suggests the use of the more reliable PHH 
system in order to estimate the inhibitory concentrations IC50 or IC90. 
In contrast to the cell-type dependent heterogeneity in the Bmax values, there was no significant 
deviation regarding the affinity of the peptide-receptor interactions. The approximate KD values 
determined by the mass-spectrometric analysis ranged from 11 nM (PRH) to 20 nM (PHH). This is in 
good agreement with the KD of ~ 60 nM as it was defined on PMH by flow cytometry. 
A general overview about the range of dissociation constants in protein-protein interactions is given 
in the table below. The affinity of HBVpreS/2-48myr(-K-FITC) to its liver-specific receptor can therefore 
be regarded as similar to that of DNA-binding proteins or a strong antibody-antigen interaction. 
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One peculiarity that remains is the high degree of binding of the mutant peptide at high 
concentrations. It is known that a myristoylation can direct proteins or peptides like e.g. pp60v-src 
(Cross et al. 1984; Kamps et al. 1985) or the retroviral Gag-protein (Göttlinger et al. 1989) to plasma 
membranes, but with a typical KD of ~ 100 µM the myristoyl residue alone is usually not sufficient to 
mediate a stable insertion into the phospholipid bilayer (see table; and (Peitzsch & McLaughlin 1993). 
For example, the KD described for the plasma membrane-interaction of a myristoylated peptide 
MGXsrc, that represents the first 11 amino acids of pp60v-src of the Rous sarcoma virus, is 
approximately 75 µM (Resh 1989). An efficient anchorage to the plasma membrane usually requires 
the cooperation of a second motif in form of an additional acylation (e.g. palmitoylation) or 
sequences that mediate a protein-protein or protein-phospholipid interaction (e.g. short 
phenylalanine- or lysine-rich stretches).  
The KD of the myristoyl-dependent interaction of HBVpreS/2-48
myr(D11,13)-K-FITC clearly lay above 2 
µM, but for technical reasons the exact affinity could not be determined (data not shown). To test if 
a second amino acid signal contributed to the membrane targeting, a peptide was synthesized that 
exhibited a scrambled amino acid sequence. However, HBVpreS/2-48myr(scrambled)-K-FITC showed 
binding dynamics that were very similar to that of HBVpreS/2-48myr(D11,13)-K-FITC (data not shown). 
An artificial cooperative effect of the FITC moiety could be excluded as another possibility to 
facilitate membrane binding, since the non-labeled mutant peptide (HBVpreS/2-48myr(D11,13)) 
showed the same non-specific binding behavior (HPLC-MS/MS experiments, Figure 15). 
 
In summary, these data imply the model of a bimodal binding mechanism: (i) The myristoylation 
facilitates binding to plasma membrane phospholipids, which can be regarded as highly abundant, 
but low affinity “non-specific” receptors (KD >> 2 µM). (ii) The amino acid sequence, in combination 
with the acyl moiety, mediates binding to the high affinity receptor (KD ~ 60 nM) which is a liver-
specific protein or at least involves a protein component, and which is essential for HBV entry. 
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Due to the low affinity the non-specific interaction does not interfere with the specific receptor-
binding at concentrations below 400 nM. Above 400 nM, it promotes an unspecific binding of 
additional peptide molecules, but does not compete with the specific preS1-receptor interaction that 
already is saturated at these concentrations (Bmax of the normalized binding curve). 
Mechanistically, one could image two additive effects of the myristoylation-dependent membrane 
interaction: (i) it might catalyze the preS1-receptor binding by reduction of the peptide diffusion to 
two dimensions and thereby enhancing the probability to collide with a specific interaction partner. 
(ii) It might further enhance the rate of successful collisions by inducing a local proximity to the 
receptor (e.g. in microdomains) and forcing the essential binding motif towards an orientation that is 
suitable to find a binding pocket on the receptor molecule. 
Consequently, the inability of HBVpreS/1-48 to bind at either concentration could be explained by 
the improbability of successful collisions without catalysis, by a direct participation of the myristoyl 
residue in the specific receptor interaction or a combination of both factors. 
4.5 Kinetic analysis of HBVpreS/2-48myr-K-FITC receptor-interaction confirmed a high affinity of 
binding and demonstrated an unusual high stability of the peptide-receptor complexes 
Analysis of the binding kinetics of HBVpreS/2-48myr-K-FITC to the plasma membranes of PHH 
demonstrated that a binding equilibrium was reached within 10 to 15 minutes after addition of 200 
nM peptide. In contrast, the infection process of an HBV particle is assumed to be relatively slow. On 
HepaRG cells, inoculation periods of 16 to 20 hours at 37°C are needed to achieve a robust infection. 
The seemingly slow kinetics of the HBV infection compared to the fast on-rate of peptide binding can 
be easily explained: The instantaneous velocity     of an association reaction between a ligand (here 
virus or peptide, respectively) and its receptor can be described in terms of the respective 
concentrations,                              , where   is the reaction rate constant. The analysis 
of the peptide binding kinetics was performed at a concentration of 200 nM - that corresponds to ~ 6 
x 1013 molecules in a 500-µl incubation volume. The standard infection of HepaRG cells is done in the 
same volume with a virus stock of approximately 1011 GE/ ml in a dilution of 1:20 to 1:25. That 
corresponds to ~ 2.5 x 109 virus particles per inoculum. The ligand concentrations differ therefore by 
more than 4 orders of magnitude. Additionally, the receptor concentrations defined as Bmax were 
shown to be significantly higher in primary hepatocytes than in HepaRG cells. Thus, the differences in 
the experimental set-up can explain the different observations. In fact, the exposition of PHH to high-
titer HBV preparations for only 1 hour resulted in unusually high infection rates (Stefan Seitz, 
personal communication). 
Furthermore, it is problematic on principle to compare the binding kinetics of a 5-kD peptide with the 
infection kinetics of complete 42-nm virus particles, particularly if the read-out of the infection relies 
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on late markers like viral proteins secreted by infected cells. The cellular receptor addressed by both 
might be better accessible to HBVpreS/2-48myr, simply due to the smaller size of this ligand. The viral 
particle in addition possibly has to overcome several obstacles before and after binding to the 
specific receptor, i.e. for instance retention at its primary attachment factors (heparan sulfate 
proteoglycans) or an abortive internalization. Taken together, there is no evidence to date that 
supports the assumption of an inefficient receptor association as limitation for the infection. 
However, it would be of high interest to investigate the kinetic binding behavior of HBV to PHH, e.g. 
by the use of fluorescently labeled particles, and to set it into relation to the peptide binding kinetics. 
Experiments addressing the stability of the peptide-receptor complexes revealed an extraordinary 
high stability over time. The fluorescent signal of receptor-associated HBVpreS/2-48myr-K-FITC could 
be monitored for more than 18 hours, with a half-life time (t1/2) of about 11 hours. Both findings 
strengthened the assumption of a high-affinity interaction and moreover demonstrated a slow 
turnover rate of the preS1-receptor-complex. Gripon et al. showed that after exposure to 
HBVpreS/2-48myr HepaRG cells regained susceptibility to HBV infection with t1/2 ~ 12 hours (Gripon et 
al. 2005). This perfectly correlated with our observations. The extraordinary high stability of 
HBVpreS/2-48myr was additionally confirmed by an in vivo study described by Alexa Schieck, who 
estimated t1/2 of HBVpreS/2-48
myr-YI131 to approximately 16 hours (Alexa Schieck, unpublished 
results).  
The mechanisms that lead to the restoration of the concentration of free receptor molecules at the 
plasma membrane remain to be elucidated. Factors involved in this process could be either a 
dissociation of the peptide-receptor complex, degradation of the peptide, or substitution of the 
sequestered target molecule by dynamic turnover (e.g. trafficking). 
4.6 Sub-cellular localization of receptor-bound HBVpreS/2-48myr revealed an interaction with 
the (actin) cytoskeleton 
High-resolution microscopy and 3-dimensional image reconstruction revealed an almost exclusive 
localization of HBVpreS/2-48myr-K-FITC at the plasma membrane of differentiated heptocytes (Figure 
17). This is in discrepancy with a previous study that suggested an uptake and intracellular 
localization of HBVpreS/2-48myr in PTH and occasionally HepG2 cells (Glebe et al. 2005). However, 
Glebe et al. used immune cytochemistry to indirectly localize preS1-peptides and moreover did not 
resolve the third dimension. Here instead, we detected fluorescently labeled peptides in a direct 
way, providing a much more authentic model system to localize binding. 
Single fluorescent spots observed within the cytoplasm were most probably derived from 
autofluorescence of the cells, since these structures were present also in absence of the peptide, and 
often represented a Golgi-like morphology. Although our experiments could not completely rule out 
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an uptake of HBVpreS/2-48myr-K-FITC, the long persistence on the plasma membrane (t1/2 ≈ 11 hours) 
and the lack of vesicular cytoplasmic structures argued against an efficient endocytosis of receptor-
bound HBVpreS/2-48myr-K-FITC. 
We furthermore could localize the preS1-receptor to the immobile fraction of the plasma membrane 
(Figure 19). By measuring recovery of fluorescence after photobleaching, the peptide-receptor 
complexes clearly showed a restricted lateral mobility, implicating an interaction with molecules that 
constrain diffusion within the membrane. The direct comparison of the lateral mobility of a 
fluorescent lipid-analog (DiI) that proved to be motile, indubitably demonstrated that there was no 
detectable lateral diffusion of the peptide-receptor complexes. Lateral mobility of membrane 
proteins in general is limited by interactions with (i) the underlying cytoskeletal network, (ii) with 
other membrane proteins or lipids, or (iii) with the extracellular matrix. For example, it has been 
shown that disruption of the cytoskeleton or use of cholesterol-depleting agents increased the lateral 
mobility of dopamine transporters in the plasma membrane (Adkins et al. 2007). Future experiments 
addressing these different possibilities with the aim to characterize the specific micro-environment 
of the preS1-receptor (e.g. by co-localization with raft markers) could contribute to the 
understanding of the virus entry and the mode of action of the inhibitory preS1-peptides. 
To further localize the peptide binding sites on a sub-cellular level, we applied high-resolution light 
microscopy such as spinning disk confocal or total internal reflection fluorescence (TIRF) microscopy. 
TIRF microscopy allowed us to visualize HBVpreS/2-48myr-C-Atto565 on live PMH with a high 
resolution down to a single-molecule level. When live PMH were monitored shortly after addition of 
the peptide, we could observe individual binding events of single molecules (or small aggregates) of 
HBVpreS/2-48myr-C-Atto565. Most of the fluorescent units thereby bound quickly and stably without 
lateral movement (Figure 18). 
Visualization of the cell-edges revealed the presence of finger-like membrane protrusions that were 
abundantly distributed over the whole cell and were associated with fluorescence. A hallmark for 
differentiated, resting hepatocytes is the formation of microvilli on the cell surface. Although this 
topic is not well understood to date, it is assumed that the tip compartments of microvilli form 
pericellular spaces on the cell surface that are separated from the cytoplasm by a tight bundle of 
actin filaments (Lange 2010). Cellular functions such as glucose transport, transmembrane ion fluxes 
and Ca2+ signaling, that are developed during growth arrest and differentiation, are assumed to 
involve a sequestration of certain transporters and ion channels to the microvilli tips (Lange & Brandt 
1990). However, the functional importance of microvilli besides an enlargement of the cell surface 
remains obscure. In order to interpret the membrane protrusions that resembled microvilli and 
bound HBVpreS/2-48myr-C-Atto565, it is inalienable to clearly identify and classify these structures for 
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instance by the use of other high-resolution microscopic techniques (e.g. stochastic optical 
reconstruction microscopy (STORM) or electron microscopy). 
Another striking observation was the detection of fluorescent clusters in TIRF and spinning disk 
confocal microscopy. Although they appeared more distinctive at the bottom side of the hepatocytes 
that is attached to the cover slip, these clusters were also abundant on the top of the membrane 
directed towards the cell-culture medium. These clusters were tightly associated with the actin 
cytoskeleton. As determined by co-localization studies using an F-actin marker, patches of actin were 
always in close proximity to the peptide-clusters (Figure 20). Thereby, actin often appeared to be 
surrounded by peptide. However, limitations in the optical resolution did not allow a more detailed 
description. 
The treatment of cells with cytochalasin D further substantiated the assumption of an actin-
interaction. Cytochalasin D acts by preventing actin polymerization (Goddette & Frieden 1986). It 
increases the number of actin filament ends and a typical sign is the formation of aggregates or foci 
that contain actin. Such foci were seen also in our experiment and the the co-localization in these 
spots seemed to be even enhanced in these spots.  
Together, these findings constitute a strong hint at a very tight connection between the actin 
cytoskeleton and the peptide-receptor complexes. Nearly all endocytic pathways that are described 
to be utilized by viruses are known to involve the (actin) cytoskeleton (review (Mercer et al. 2010). 
Since the peptide-receptor complexes interact with the cytoskeleton either in a direct or indirect way 
through adaptor proteins, it is likely that actin plays a role in the entry of HBV. 
4.7 Visualization of HBV particles 
In order to employ the findings made by the visualization of HBVpreS/2-48myr to the analysis of the 
HBV-cell interaction, and to investigate HBV entry by tracking single particles, we here describe the 
initial production and characterization of fluorescently labeled particles that can be used in future 
tracking experiments. 
Single virus tracking (SVT) represents an ideal, but technically demanding method to investigate virus 
entry. The direct observation of fluorescently labeled virus particles in real-time, as described in the 
past years for many viruses, like e.g. influenza (Lakadamyali et al. 2003), polyoma virus (Ewers et al. 
2005) or SV40 (Pelkmans et al. 2001), has helped a lot to understand the viral entry processes and 
kinetics. In contrast to other microscopic techniques that rely on sample fixation 
(immunofluorescence, electron microscopy) or to biochemical assays, SVT directly monitors the 
interactions of particles and cells on live cells. It therefore reflects the in vivo situation much better. 
However, fluorescently labeled virus particles need to fulfill several prerequisites to be suited for 
SVT. On the one hand, the fluorescent label must be bright and stable enough to trace the particle 
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over potentially long observation periods. On the other hand, the particle itself must not be altered 
in a way that its normal functionality, i.e. infectivity, is significantly altered. 
There are several ways to label a virus particle, such as genetic engineering by expression of 
fluorescent viral fusionproteins, the attachment of chemical dyes to proteins or nucleic acids, or the 
incorporation of fluorescent lipid-analogs into viral envelopes.  For HBV, the possibilities of particle 
labeling are extremely restricted. Due to its complex and small sized genome it is difficult to 
incorporate fluorescent proteins without interfering with particle assembly. It has been shown that 
an N-terminal fusion of GFP to the S-protein is tolerated when co-expressed and co-integrated 
together with the wild type S-protein (Lambert et al. 2004). However, infectivity of these particles 
has not been shown. Further attempts to label HBV with lipid analoga like DiI, or DiO resulted in the 
detection of fluorescence on a cellular but not a single particle level (Kerry Mills, unpublished data).  
One approach that was followed here was the labeling of HBV particles by an incorporation of 
fluorescently labeled lipids (phosphoethanolamine-FITC). Although this method produced fluorescent 
particles that could be characterized as single particles, they were not suited for live-cell imaging 
since infectivity could not be demonstrated yet and FITC bleached rapidly. 
In a second approach, we established a method to label HBV particles from HepAD38 supernatant 
with a stable and protein-reactive derivate of Alexa-Fluor488. A procedure that combined gel 
filtration, affinity chromatography and density gradient centrifugation yielded fluorescently labeled, 
HBV particles (HBV-Alexa488). 
The concomitant detection of HBV-DNA, fluorescence and HBV-proteins in the peak fractions of 
sucrose-density gradients indicated the presence of fluorescent HBV particles. Significant 
contamination of the fractions with protein could be excluded by silver gel analysis (Figure 21). 
The infectivity of HBV-Alexa488 preparations was confirmed for three different preparations on 
HepaRG cells. However, it would be necessary for future experiments to determine the multiplicity of 
infection by comparing HBV-Alexa488 infectivity with that of an equally produced, unlabeled HBV. In 
this context, it would be also important to determine the percentage of unlabeled particles within a 
preparation. 
Confocal microscopy showed that HBV-Alexa488 could be detected as single particles. The 
fluorescence intensity profiles of these particles revealed that single particles could be distinguished 
from aggregates by their fluorescence distribution. A spherically shaped fluorescent particle emits 
concentric, circular fluorescence that decreases in intensity with the radius. The distribution of the 
fluorescence intensity of a single particle therefore shows characteristics of a Gaussian distribution. 
The profiles of single particles were represented a Gaussian curve and a diameter of approximately 
200 - 300 nm (Figure 22). In contrast, aggregates imaged under equal microscopic settings, showed a 
broader distribution of fluorescence (Ø > 600 nm) and sometimes two peaks. This is a result from at 
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least two overlapping Gaussian distribution curves that due to the optical limitations of the system 
could not be separated from each other. 
Quantitative analysis of the distribution of particle sizes within a preparation revealed that the vast 
amount of particles was small-sized (~ 8 nm2). Aggregates were present but not abundant. 
First attempts to visualize HBV-Alexa488 on HepaRG cells showed that particle fluorescence was 
bright and punctuated enough to be distinguished from autofluorescence in fixed cells. To 
demonstrate the comparability of HBV-Alexa488 with unlabeled HBV, we checked if established 
characteristics of HBV infection can also be attributed to HBV-Alexa488 (Figure 24). It has been 
shown that the addition of PEG during virus inoculation markedly increased the infection process by 
enhancing particle binding (presumably to GAGs) (Gripon et al. 1993b). This effect could be visualized 
for the first time on a single-particle level, since HBV-Alexa488 binding to HepaRG cells was 
significantly enhanced in presence of PEG. A second well characterized feature is the HBV infection 
inhibition by highly sulfated GAGs (Schulze et al. 2007). Heparin, a prototypic member of the GAGs, 
has been shown to interfere with HBV binding at high concentrations. We here demonstrated that 
also HBV-Alexa488 binding can be inhibited by heparin. Although the effects of PEG and heparin are 
rather unspecific, our experiments represented a first indication that HBV-Alexa488 showed high 
similarity to the unlabeled virus. Assays with e.g. neutralizing antibodies, or the use of entry 
inhibitors could provide more secure evidence of a specificity of the interaction. 
When analyzed in a 3-dimensional approach, particles were found to be located almost exclusively at 
the plasma membrane. Only some fluorescent particles were observed within the cytoplasm, but 
these have to be further quantified and identified. However, massive endocytosis of the particles was 
not observed despite the incubation at 37°C for 1.5 hours. Although being consistent with the data 
for HBVpreS/2-48myr-K-FITC (see Figure 16 and Figure 18), it is not possible to directly compare the 
binding behavior of the peptide and HBV-Alexa488 since the latter involves e.g. an additional binding 
to proteoglycans. 
Unspecific binding to proteoglycans also might be the reason why binding of HBV-Alexa488 was not 
restricted to differentiated cells within the HepaRG culture. 
In summary, it could be shown that fluorescently labeled, infectious HBV particles can be produced 
with a high purity. Although aggregates were present in the preparations, the bigger part represents 
single particles showing a fluorescence that can be detected on HepaRG cells. Our data therefore 
suggest the suitability of HBV-Alexa488 for a future real-time analysis of the HBV-cell interactions.
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